Document:

Exhibit 10.1

SUBSCRIPTION
AGREEMENT

This
SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is entered into on April 28, 2022, by and between Ignyte
Acquisition Corp., a Delaware corporation (“Ignyte”), and the undersigned subscriber (the “Investor”).

WHEREAS,
this Subscription Agreement is being entered into in connection with the Business Combination Agreement, dated as of the date
hereof (as may be amended, supplemented or otherwise modified from time to time, the “Transaction Agreement”),
by and between Ignyte, Ignyte Korea Co., Ltd., a corporation organized under the laws of the Republic of Korea (“Merger
Sub”) and Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea (the “Company,”
and together with Ignyte and Merger Sub, the “Parties”), pursuant to which, among other things, the Parties
desire to enter into a business combination transaction (such transaction, together with the other transactions contemplated by,
and subject to the terms and conditions of, the Transaction Agreement, collectively, the “Transaction”) structured
as a comprehensive share swap whereby (i) the stockholders of the Company will transfer their respective shares of common stock
of the Company, par value KRW 500 per share (the “Company Common Stock”), to Merger Sub in exchange for shares
of common stock of Ignyte, par value $0.0001 per share (the “Ignyte Common Stock”) held by Merger Sub, and
(ii) in the course of such share swap, Merger Sub will contribute the shares of Company Common Stock to Ignyte in consideration
of Ignyte Common Stock (which will in-turn be distributed to the stockholders of the Company as described in (i) above);

WHEREAS,
in connection with the Transaction, Ignyte is seeking commitments from interested investors to purchase shares of Ignyte Common
Stock (the “Shares”), in a private placement for a purchase price of $10.00 per share (the “Per Share
Subscription Price”);

WHEREAS,
the aggregate purchase price to be paid by the Investor for the subscribed Shares (as set forth on the signature page hereto)
is referred to herein as the “Subscription Amount”; and

WHEREAS, substantially concurrently with the execution
of this Subscription Agreement, Ignyte is entering into separate subscription and purchase agreements (collectively, the “Other
Subscription Agreements”) with certain investors (the “Other Investors”) with an aggregate purchase
price of $25,000,000 (inclusive of the Subscription Amount) (the “PIPE Investment”).

NOW,
THEREFORE, in consideration of the foregoing and the mutual representations, warranties and covenants, and subject to the conditions,
set forth herein, and intending to be legally bound hereby, each of the Investor and Ignyte acknowledges and agrees as follows:

1.
Subscription. The Investor hereby irrevocably subscribes for and agrees to purchase from Ignyte, and Ignyte agrees to issue
and sell to the Investor, the number of Shares set forth on the signature page of this Subscription Agreement on the terms and
subject to the conditions provided for herein.

2. Closing.
The closing of the sale of the Shares contemplated hereby (the “Closing”) shall occur on a closing date
(the “Closing Date”) specified in the Closing Notice (as defined below), and the Closing shall be
conditioned upon the prior or substantially concurrent consummation of the Transaction (the closing date of the
Transaction, the “Transaction Closing Date”). Upon delivery of written notice from (or on behalf of)
Ignyte to the Investor (the “Closing Notice”), that Ignyte reasonably expects all conditions to the
closing of the Transaction to be satisfied or waived on an expected Transaction Closing Date that is not less than five (5)
business days from the date on which the Closing Notice is delivered to the Investor, the Investor shall deliver the
Subscription Amount three (3) business days prior to the expected Closing Date by wire transfer of United States dollars in
immediately available funds to the account(s) specified by Ignyte in the Closing Notice. On the Closing Date, Ignyte shall
issue the Shares to the Investor and subsequently cause the Shares to be registered in book entry form in the name of the
Investor and will provide to the Investor, upon request by the Investor, evidence of such issuance from Ignyte’s
transfer agent. For purposes of this Subscription Agreement, “business day” shall mean a day, other than a
Saturday, Sunday or other day on which commercial banks in New York, New York are authorized or required by law to close.
Prior to or at the Closing, the Investor shall deliver to Ignyte a duly completed and executed Internal Revenue Service Form
W-9 or appropriate Form W-8. In the event the Transaction Closing Date does not occur within two (2) business days after the
Closing Date under this Subscription Agreement, Ignyte shall promptly (but not later than two (2) business days
thereafter) return the Subscription Amount to the Investor by wire transfer of U.S. dollars in immediately available funds to
the account specified by the Investor, and any book-entries for the Shares shall be deemed cancelled; provided that,
unless this Subscription Agreement has been terminated pursuant to Section 9 hereof, such return of funds shall not
terminate this Subscription Agreement or relieve the Investor of its obligation to purchase the Shares at the Closing in the
event Ignyte delivers a subsequent Closing Notice in accordance with this Section 2.

3.
Closing Conditions. The obligation of the parties hereto to consummate the purchase and sale of the Shares pursuant to
this Subscription Agreement is subject to the following conditions: (a) there shall not be in force any injunction or order enjoining
or prohibiting the issuance and sale of the Shares under this Subscription Agreement; (b) except to the extent consented to in
writing by the Investor, no amendments of, or waivers under, the Transaction Agreement (as the same exists as of the date of this
Subscription Agreement) (including the conditions thereto) shall have occurred that materially and adversely affect the economic
benefits the Investor (in its capacity as such) would reasonably expect to receive under this Subscription Agreement; and (c)(i)
solely with respect to the Investor’s obligation to close, the representations and warranties made by Ignyte, and (ii) solely
with respect to the Ignyte’s obligation to close, the representations and warranties made by the Investor, in each case,
in this Subscription Agreement shall be true and correct in all material respects as of the Closing Date other than (x) those
representations and warranties qualified by materiality, Material Adverse Effect (as defined below) or similar qualification,
which shall be true and correct in all respects as of the Closing Date and (y) those representations and warranties expressly
made as of an earlier date, which shall be true and correct in all material respects (or, if qualified by materiality, Material
Adverse Effect or similar qualification, all respects) as of such date, in each case without giving effect to the consummation
of the Transaction.

4.
Further Assurances. At the Closing, the parties hereto shall execute and deliver such additional documents and take such
additional actions as the parties reasonably may deem to be practical and necessary in order to consummate the subscription as
contemplated by this Subscription Agreement.

5.
Ignyte Representations and Warranties. Ignyte represents and warrants to the Investor that:

(a) Ignyte was duly incorporated
and is validly existing and in good standing under the laws of the State of Delaware. Ignyte has all power (corporate or otherwise)
and authority to own, lease and operate its properties and conduct its business as presently conducted and to enter into, deliver
and perform its obligations under this Subscription Agreement.

(b)
As of the Closing Date, the Shares will be duly authorized and, when issued and delivered to the Investor against full payment
therefor in accordance with the terms of this Subscription Agreement, the Shares will be validly issued, fully paid and non-assessable
and will not have been issued in violation of or subject to any preemptive or similar rights created under Ignyte’s organizational
documents (as in effect at such time of issuance) or under the Delaware General Corporation Law.

(c)
This Subscription Agreement has been duly authorized, executed and delivered by Ignyte and, assuming that this Subscription Agreement
constitutes the valid and binding agreement of the Investor, this Subscription Agreement is enforceable against Ignyte in accordance
with its terms, except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium or other laws relating to or affecting the rights of creditors generally, or (ii) principles of equity, whether considered
at law or equity.

(d)
The issuance and sale by Ignyte of the Shares pursuant to this Subscription Agreement will not (i) conflict with or result in
a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition
of any lien, charge or encumbrance upon any of the property or assets of Ignyte or any of its subsidiaries pursuant to the terms
of any indenture, mortgage, deed of trust, loan agreement, lease, license or other agreement or instrument to which Ignyte or
any of its subsidiaries is a party or by which Ignyte or any of its subsidiaries is bound or to which any of the property or assets
of Ignyte is subject that would reasonably be expected to have a material adverse effect on the business, financial condition
or results of operations of Ignyte and its subsidiaries, taken as a whole (a “Material Adverse Effect”), or
materially and adversely affect the validity of the Shares or the legal authority of Ignyte to comply in all material respects
with its obligations under this Subscription Agreement; (ii) result in any violation of the provisions of the organizational documents
of Ignyte; or (iii) result in any violation of any statute or any judgment, order, rule or regulation of any court or governmental
agency or body, domestic
or foreign, having jurisdiction over Ignyte or any of its properties that would reasonably be expected to have a Material Adverse
Effect or materially and adversely affect the validity of the Shares or the legal authority of Ignyte to comply in all material
respects with its obligations under this Subscription Agreement.

2

(e)
As of their respective filing dates, or, if amended, as of the date of such amendment, which shall be deemed to supersede such
original filing, all reports required to be filed by Ignyte with the U.S. Securities and Exchange Commission (the “SEC”)
since January 28, 2021 (the “SEC Reports”) complied in all material respects with the applicable requirements
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations of the
SEC promulgated thereunder. None of the SEC Reports filed under the Exchange Act included, when filed or, if amended, as of the
date of such amendment with respect to those disclosures that are amended, any untrue statement of a material fact or omitted
to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made,
not misleading; provided, that Ignyte makes no such representation or warranty with respect to any registration statement or any
proxy statement/prospectus to be filed by Ignyte with respect to the Transaction or any other information relating to the Company
or any of its affiliates Ignyte included in any SEC Report or filed as an exhibit thereto. Ignyte has timely filed with the SEC
each SEC Report that Ignyte was required to file with the SEC. As of the date hereof, there are no material outstanding or unresolved
comments in comment letters received by Ignyte from the staff of the Division of Corporation Finance of the SEC with respect to
any of the SEC Reports. Notwithstanding the foregoing, this representation and warranty shall not apply to any statement or information
in the SEC Reports that relates to (i) the topics referenced in the SEC’s “Staff Statement on Accounting and Reporting
Considerations for Warrants Issued by Special Purpose Acquisition Companies” on April 12, 2021 or any subsequent guidance,
statements or interpretations issued by the SEC or the Staff (collectively, the “SEC Statement”) or (ii) the Company’s
outstanding redeemable shares as temporary, as opposed to permanent, equity (“Redeemable Share Classification Changes”).
Neither any correction, amendment or restatement of Ignyte’s financial statements due to the SEC Statement, Redeemable Share
Classification Changes or to other accounting matters related to initial public offering securities or expenses, nor any changes
in accounting or disclosure related thereto, shall be deemed to be a breach of any representation or warranty by Ignyte.

(f)
Ignyte is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or
registration with, any court or other federal, state, local or other governmental authority, self-regulatory organization or
other person in connection with the issuance of the Shares pursuant to this Subscription Agreement, other than (i) filings
with the SEC, (ii) in connection with or as a result of the SEC Statement or Redeemable Share Classification Changes, (iii)
filings required by applicable state securities laws, (iv) the filings required in accordance with Section 13 of this
Subscription Agreement; (v) those required by the New York Stock Exchange or Nasdaq, as applicable, including with respect to
obtaining approval of Ignyte’s stockholders, (vi) the filing of a notification under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, if applicable, and (vii) the failure of which to obtain would not be reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect.

(g)
As of the date hereof, Ignyte has not received any written communication from a governmental authority that alleges that Ignyte
is not in compliance with or is in default or violation of any applicable law, except where such non-compliance, default or violation
would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

(h)
Assuming the accuracy of the Investor’s representations and warranties set forth in Section 6 of this
Subscription Agreement, no registration under the Securities Act of 1933, as amended (the “Securities
Act”), is required for the offer and sale of the Shares by Ignyte to the Investor.

(i)
Neither Ignyte nor any person acting on its behalf has offered or sold the Shares by any form of general solicitation or general
advertising in violation of the Securities Act.

(j)
As of the date hereof, the issued and outstanding shares of Ignyte Common Stock are registered pursuant to Section 12(b) of the
Exchange Act and are listed for trading on Nasdaq. There is no suit, action, proceeding or investigation pending or, to the knowledge
of Ignyte, threatened against Ignyte by Nasdaq or the SEC with respect to any intention by such entity to deregister the Shares
or prohibit or terminate the listing of the Shares on Nasdaq, excluding, for the purposes of clarity, the customary ongoing review
by Nasdaq in connection with the Transaction.
Ignyte has taken no action that is designed to terminate the registration of the Shares under the Exchange Act prior to the Closing.

3

(k)
Ignyte is not under any obligation to pay any broker’s fee or commission in connection with the sale of the Shares.

(l)
The Other Subscription Agreements reflect the same Per Share Subscription Price and other terms with respect to the purchase of
the Shares that are not materially more favorable to such Other Investor thereunder than the terms of this Subscription Agreement,
other than terms particular to the regulatory requirements of such Other Investor or its affiliates or related funds.

6.
Investor Representations and Warranties. The Investor represents and warrants to Ignyte that:

(a) The Investor (i) is a
“qualified institutional buyer” (as defined in Rule 144A under the Securities Act) or an “accredited investor”
(within the meaning of Rule 501(a) under the Securities Act), in each case, satisfying the applicable requirements set forth on
Schedule A, (ii) is acquiring the Shares only for its own account and not for the account of others, or if the Investor
is subscribing for the Shares as a fiduciary or agent for one or more investor accounts, each owner of such account is a “qualified
institutional buyer” (as defined in Rule 144A under the Securities Act) or an “accredited investor” (within
the meaning of Rule 501(a) under the Securities Act) and the Investor has full investment discretion with respect to each such
account, and the full power and authority to make the acknowledgements, representations and agreements herein on behalf of each
owner of each such account, and (iii) is not acquiring the Shares with a view to, or for offer or sale in connection with, any
distribution thereof in violation of the Securities Act or the laws of any jurisdiction (and shall provide the requested information
set forth on Schedule A). The Investor is not an entity formed for the specific purpose of acquiring the Shares and is
an “institutional account” as defined by FINRA Rule 4512(c).

(b)
The Investor acknowledges and agrees that the Shares are being offered in a transaction not involving any public offering
within the meaning of the Securities Act, that the Shares have not been registered under the Securities Act and that Ignyte
is not required to register the Shares except as set forth in Section 8 of this Subscription Agreement. The Investor
acknowledges and agrees that the Shares may not be offered, resold, transferred, pledged or otherwise disposed of by the
Investor absent an effective registration statement under the Securities Act except (i) to Ignyte or a subsidiary thereof,
(ii) to non-U.S. persons pursuant to offers and sales that occur outside the United States within the meaning of Regulation S
under the Securities Act or (iii) pursuant to Rule 144 under the Securities Act or another applicable exemption from the
registration requirements of the Securities Act, and, in each case, in accordance with any applicable securities laws of the
states of the United States and other applicable jurisdictions, and that any certificates or book entries representing the
Shares shall contain a restrictive legend to such effect. The Investor acknowledges and agrees that the Shares will be
subject to the foregoing transfer restrictions and, as a result of these transfer restrictions, the Investor may not be able
to readily offer, resell, transfer, pledge or otherwise dispose of the Shares and may be required to bear the financial risk
of an investment in the Shares for an indefinite period of time. The Investor acknowledges and agrees that the Shares will
not immediately be eligible for offer, resale, transfer, pledge or disposition pursuant to Rule 144 promulgated under the
Securities Act, and that the provisions of Rule 144(i) will apply to the Shares. The Investor acknowledges and agrees that it
has been advised to consult legal, tax and accounting advisors prior to making any offer, resale, transfer, pledge or
disposition of any of the Shares.

(c)
The Investor acknowledges and agrees that the Investor is purchasing the Shares from Ignyte. The Investor further acknowledges
that there have been no representations, warranties, covenants and agreements made to the Investor by or on behalf of Ignyte,
the Company, any of their respective affiliates or any control persons, officers, directors, employees, agents or representatives
of any of the foregoing or any other person or entity, expressly or by implication, other than those representations, warranties,
covenants and agreements of Ignyte expressly set forth in Section 5 of this Subscription Agreement.

(d)
The Investor acknowledges and agrees that the Investor has received such information as the Investor deems necessary in order
to make an investment decision with respect to the Shares, including, with respect to Ignyte, the Transaction and the business
of the Company and its subsidiaries. Without limiting the generality of the foregoing, the Investor acknowledges that it has reviewed
Ignyte’s filings with the SEC. The Investor acknowledges
and agrees that the Investor and the Investor’s professional advisor(s), if any, have had the full opportunity to ask such
questions, receive such answers and obtain such information as the Investor and the Investor’s professional advisor(s),
if any, have deemed necessary to make an investment decision with respect to the Shares. 

4

(e)
The Investor became aware of this offering of the Shares solely by means of direct contact between the Investor and Ignyte,
the Company or a representative of Ignyte or the Company, and the Shares were offered to the Investor solely by direct
contact between the Investor and Ignyte, the Company or a representative of Ignyte or the Company. The Investor did not
become aware of this offering of the Shares, nor were the Shares offered to the Investor, by any other means. The Investor
acknowledges that the Shares (i) were not offered by any form of general solicitation or general advertising and (ii) are not
being offered in a manner involving a public offering under, or in a distribution in violation of, the Securities Act, or any
state securities laws. The Investor acknowledges that there have not been, and the Investor hereby agrees that it is not
relying upon, and has not relied upon, any statement, covenant, agreement, representation or warranty made by any person,
firm or corporation (including, without limitation, Ignyte, the Company, any of their respective affiliates or any control
persons, officers, directors, employees, agents, representatives, legal counsel, financial advisors or accountants of any of
the foregoing), other than the representations and warranties of Ignyte contained in Section 5 of this Subscription
Agreement, in making its investment or decision to invest in Ignyte.

(f)
The Investor acknowledges that it is aware that there are substantial risks incident to the purchase and ownership of the Shares,
including those set forth in Ignyte’s filings with the SEC. The Investor has such knowledge and experience in financial
and business matters as to be capable of evaluating the merits and risks of an investment in the Shares, and the Investor has
sought such accounting, legal and tax advice as the Investor has considered necessary to make an informed investment decision.
The Investor acknowledges that the Investor shall be responsible for any of the Investor’s tax liabilities that may arise
as a result of the transactions contemplated by this Subscription Agreement, and that neither Ignyte nor the Company has provided
any tax advice or any other representation or guarantee regarding the tax consequences of the transactions contemplated by the
Subscription Agreement.

(g)
Alone, or together with any professional advisor(s), the Investor has adequately analyzed and fully considered the risks of an
investment in the Shares and determined that the Shares are a suitable investment for the Investor and that the Investor is able
at this time and in the foreseeable future to bear the economic risk of a total loss of the Investor’s investment in Ignyte.
The Investor acknowledges specifically that a possibility of total loss exists.

(h)
In making its decision to purchase the Shares, the Investor has relied solely upon independent investigation made by the Investor
and the representations and warranties of Ignyte in Section 5.

(i)
The Investor acknowledges and agrees that no federal or state agency has passed upon or endorsed the merits of the offering of
the Shares or made any findings or determination as to the fairness of this investment.

(j)
The Investor has been duly formed or incorporated and is validly existing and is in good standing under the laws of its jurisdiction
of formation or incorporation, with power and authority to enter into, deliver and perform its obligations under this Subscription
Agreement.

(k)
The execution, delivery and performance by the Investor of this Subscription Agreement, the purchase of the Shares hereunder,
the compliance by the Investor with all of the provisions of this Subscription Agreement and the consummation of the transactions
contemplated herein are within the powers of the Investor, have been duly authorized and will not constitute or result in a breach,
violation or default, conflict with or result in the creation or imposition of any lien, charge or encumbrance upon any of the
property or assets of the Investor pursuant to the terms of (a) any order, ruling or regulation of any court or other tribunal
or of any governmental commission or agency, (b) any indenture, mortgage, deed of trust, loan agreement, lease, license or other
agreement or undertaking, to which the Investor is a party, by which the Investor is bound or to which any of the property or
assets of the Investor is subject, and (c) if the Investor is not an individual, the Investor’s organizational documents,
including, without limitation, its incorporation or formation papers, bylaws, indenture of trust or partnership or operating agreement,
as may be applicable. The signature of the Investor on this Subscription Agreement
is genuine, and the signatory has legal competence and capacity to execute the same or the signatory has been duly authorized
to execute the same, and, assuming that this Subscription Agreement constitutes the valid and binding agreement of Ignyte, this
Subscription Agreement constitutes a legal, valid and binding obligation of the Investor, enforceable against the Investor in
accordance with its terms except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance,
reorganization, moratorium or other laws relating to or affecting the rights of creditors generally, and (ii) principles of equity,
whether considered at law or equity.

5

(l)
Neither the Investor nor, if the Investor is not an individual, any of its officers, directors, managers, managing members, general
partners or any other person acting in a similar capacity or carrying out a similar function, is (i) a person named on the Specially
Designated Nationals and Blocked Persons List, the Foreign Sanctions Evaders List, the Sectoral Sanctions Identification List,
or any other similar list of sanctioned persons administered by the U.S. Treasury Department’s Office of Foreign Assets
Control (“OFAC”), or any similar list of sanctioned persons administered by the European Union or any individual
European Union member state, including the United Kingdom (collectively, “Sanctions Lists”); (ii) directly
or indirectly owned or controlled by, or acting on behalf of, one or more persons on a Sanctions List; (iii) organized, incorporated,
established, located or resident, or a citizen, national, or the government, including any political subdivision, agency, or instrumentality
thereof, of, Cuba, Iran, North Korea, Syria, Venezuela, the Crimea region of Ukraine, or any other country or territory embargoed
or subject to substantial trade restrictions by the United States, the European Union or any individual European Union member
state, including the United Kingdom; (iv) a Designated National as defined in the Cuban Assets Control Regulations, 31 C.F.R.
Part 515; or (v) a non-U.S. shell bank or providing banking services indirectly to a non-U.S. shell bank (collectively, a “Prohibited
Investor”). The Investor represents that if it is a financial institution subject to the Bank Secrecy Act (31 U.S.C.
Section 5311 et seq.) (the “BSA”), as amended by the USA PATRIOT Act of 2001 (the “PATRIOT Act”),
and its implementing regulations (collectively, the “BSA/PATRIOT Act”), that the Investor maintains policies
and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. The Investor also represents
that it maintains policies and procedures reasonably designed to ensure compliance with sanctions administered by the United States,
the European Union, or any individual European Union member state, including the United Kingdom, to the extent applicable to it.
The Investor further represents that the funds held by the Investor and used to purchase the Shares were legally derived and were
not obtained, directly or indirectly, from a Prohibited Investor.

(m)
If the Investor is or is acting on behalf of (i) an employee benefit plan that is subject to Title I of the Employee Retirement
Income Security Act of 1974, as amended (“ERISA”), (ii) a plan, an individual retirement account or other arrangement
that is subject to Section 4975 of the Internal Revenue Code of 1986, as amended (the “Code”), (iii) an entity
whose underlying assets are considered to include “plan assets” of any such plan, account or arrangement described
in clauses (i) and (ii) (each, an “ERISA Plan”), or (iv) an employee benefit plan that is a governmental plan
(as defined in Section 3(32) of ERISA), a church plan (as defined in Section 3(33) of ERISA), a non-U.S. plan (as described in
Section 4(b)(4) of ERISA) or other plan that is not subject to the foregoing clauses (i), (ii) or (iii) but may be subject to
provisions under any other federal, state, local, non-U.S. or other laws or regulations that are similar to such provisions of
ERISA or the Code (collectively, “Similar Laws,” and together with ERISA Plans, “Plans”),
the Investor represents and warrants that (A) neither Ignyte nor any of its affiliates has provided investment advice or has otherwise
acted as the Plan’s fiduciary, with respect to its decision to acquire and hold the Shares, and none of the parties to the
Transaction is or shall at any time be the Plan’s fiduciary with respect to any decision in connection with the Investor’s
investment in the Shares; and (B) its purchase of the Shares will not result in a non-exempt prohibited transaction under Section
406 of ERISA or Section 4975 of the Code, or any applicable Similar Law.

(n)
The Investor is not a foreign person (as defined in 31 C.F.R. Part 800.224) in which the national or subnational governments of
a single foreign state have a substantial interest (as defined in 31 C.F.R. Part 800.244).

(o)
The Investor has or has commitments to have and, when required to deliver payment to Ignyte pursuant to Section 2
above, will have, sufficient funds to pay the Subscription Amount and consummate the purchase and sale of the Shares pursuant
to this Subscription Agreement.

6

(p)
The Investor acknowledges that Ignyte continues to review the SEC Statement, Redeemable Share Classification Changes and their
respective implications, including on the financial statements and other information included in its SEC Reports, and any restatement,
revision or other modification of the SEC Reports relating to or arising from such review, any subsequent related agreements or
any other guidance from the Staff of the SEC with respect to the SEC Statement or Redeemable Share Classification Changes shall
be deemed not material for purposes of this Agreement.

(q)
No broker or finder is entitled to any brokerage or finder’s fee or commission payable by the Investor solely in connection
with the sale of the Shares to the Investor based on any arrangement entered into by or on behalf of the Investor.

7.
No Hedging. The Investor hereby agrees that neither it, its controlled affiliates, nor any person or entity acting on its
or its controlled affiliates’ behalf or pursuant to any understanding with it, shall execute any short sales (as such term
is defined in Regulation SHO under the Exchange Act, 17 CFR 242.200) or engage in other hedging transactions of any kind with
respect to the Shares during the period from the date of this Subscription Agreement through the Closing date (or such earlier
termination of this Subscription Agreement). Nothing in this Section 7 shall prohibit (x) any other investment portfolios or departments
or groups of Investor that have no knowledge of this Subscription Agreement or of the Investor’s participation in this transaction
and have not been informed by the Investor of the Transaction (including Investor’s controlled affiliates and/or affiliates)
from entering into any short sales or engaging in other hedging transactions or (y) any portfolio company or third-party investment
manager engaged by Investor that may engage in any short sales or hedging transactions on Investor’s behalf, if such portfolio
company or third-party investment manager has not been directed or instructed to engage in short sales or hedging transactions
with respect to the Shares by the Investor or any of the persons that are subject to the foregoing.

8. Registration
Rights.

(a)
Ignyte agrees that, within thirty (30) calendar days following the Closing Date (such deadline, the “Filing
Deadline”), Ignyte will submit to or file with the SEC a registration statement for a shelf registration on Form
S-1 or Form S-3 (if Ignyte is then eligible to use a Form S-3 shelf registration) (the “Registration
Statement”), in each case, covering the resale of the Shares acquired by the Investor pursuant to this Subscription
Agreement which are eligible for registration (determined as of two (2) business days prior to such submission or filing)
(the “Registrable Shares”) and Ignyte shall use its commercially reasonable efforts to have the
Registration Statement declared effective as soon as practicable after the filing thereof, but no later than the earlier of
(i) the 90th calendar day following the filing date thereof if the SEC notifies Ignyte that it will “review” the
Registration Statement and (ii) the 10th business day after the date Ignyte is notified (orally or in writing, whichever is
earlier) by the SEC that the Registration Statement will not be “reviewed” or will not be subject to further
review (such earlier date, the “Effectiveness Deadline”); provided, however, that
Ignyte’s obligations to include the Registrable Shares in the Registration Statement are contingent upon the Investor
furnishing in writing to Ignyte such information regarding the Investor or its permitted assigns, the securities of Ignyte
held by the Investor and the intended method of disposition of the Registrable Shares (which shall be limited to
non-underwritten public offerings) as shall be reasonably requested by Ignyte to effect the registration of the Registrable
Shares, and the Investor shall execute such documents in connection with such registration as Ignyte may reasonably request
that are customary of a selling stockholder in similar situations, including providing that Ignyte shall be entitled to
postpone and suspend the effectiveness or use of the Registration Statement, if applicable, as permitted hereunder; provided
that the Investor shall not in connection with the foregoing be required to execute any lock-up or similar agreement or
otherwise be subject to any contractual restriction on the ability to transfer the Registrable Shares. For as long as the
Investor holds Shares, Ignyte will use commercially reasonable efforts to file all reports for so long as the condition in
Rule 144(c)(1) (or Rule 144(i)(2), if applicable) is required to be satisfied, and provide all customary and reasonable
cooperation, necessary to enable the undersigned to resell the Shares pursuant to Rule 144 under the Securities Act (in each
case, when Rule 144 under the Securities Act becomes available to the Investor). Any failure by Ignyte to file the
Registration Statement by the Filing Deadline or to effect such Registration Statement by the Effectiveness Deadline shall
not otherwise relieve Ignyte of its obligations to file or effect the Registration Statement as set forth above in this Section
8.

(b) At
its expense Ignyte shall:

7

(i)
except for such times as Ignyte is permitted hereunder to suspend the use of the prospectus forming part of a Registration Statement,
use its commercially reasonable efforts to keep such registration, and any qualification, exemption or compliance under state
securities laws which Ignyte determines to obtain, continuously effective with respect to the Investor, and to keep the applicable
Registration Statement or any subsequent shelf registration statement free of any material misstatements or omissions, until the
earlier of the following: (A) the Investor ceases to hold any Registrable Shares, (B) the date all Registrable Shares held by
the Investor may be sold without restriction under Rule 144, including without limitation, any volume and manner of sale restrictions
which may be applicable to affiliates under Rule 144 under the Securities Act and without the requirement for Ignyte to be in
compliance with the current public information required under Rule 144(c)(1) (or Rule 144(i)(2), if applicable) under the Securities
Act, and (C) two (2) years from the date of effectiveness of the Registration Statement. The period of time during which Ignyte
is required hereunder to keep a Registration Statement effective is referred to herein as the “Registration Period”;

(ii) during the Registration Period, advise the Investor, as expeditiously as possible:

(1) when a Registration Statement or any
amendment thereto has been filed with the SEC;

(2) after it shall receive notice or obtain knowledge thereof, of the issuance
by the SEC of any stop order suspending the effectiveness of any Registration Statement or the initiation of any proceedings for
such purpose;

(3) of the receipt by Ignyte of any notification with respect to the suspension of the qualification of the Registrable
Shares included therein for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and

(4) subject to the provisions in this Subscription Agreement, of the occurrence of any event that requires the making of any changes
in any Registration Statement or prospectus so that, as of such date, the statements therein are not misleading and do not omit
to state a material fact required to be stated therein or necessary to make the statements therein (in the case of a prospectus,
in the light of the circumstances under which they were made) not misleading.

Notwithstanding
anything to the contrary set forth herein, Ignyte shall not, when so advising the Investor of such events, provide the Investor
with any material, nonpublic information regarding Ignyte other than to the extent that providing notice to the Investor of the
occurrence of the events listed in (1) through (4) above constitutes material, nonpublic information regarding Ignyte;

(iii)
during the Registration Period, use its commercially reasonable efforts to obtain the withdrawal of any order suspending the effectiveness
of any Registration Statement as soon as reasonably practicable;

(iv)
during the Registration Period, upon the occurrence of any event contemplated in Section 8(b)(ii)(4) above, except for
such times as Ignyte is permitted hereunder to suspend, and has suspended, the use of a prospectus forming part of a
Registration Statement, Ignyte shall use its commercially reasonable efforts to as soon as reasonably practicable prepare a
post-effective amendment to such Registration Statement or a supplement to the related prospectus, or file any other required
document so that, as thereafter delivered to purchasers of the Registrable Shares included therein, such prospectus will not
include any untrue statement of a material fact or omit to state any material fact necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading;

(v)
during the Registration Period, use its commercially reasonable efforts to cause all Registrable Shares to be listed on each securities
exchange or market, if any, on which the Shares have been listed;

(vi) during the Registration Period, use its commercially reasonable
efforts to allow the Investor to review disclosure regarding the Investor in the Registration Statement; and

8

(vii)
during the Registration Period, otherwise, in good faith, cooperate reasonably with, and take such customary actions as may reasonably
be requested by the Investor, consistent with the terms of this Agreement, in connection with the registration of the Registrable
Shares.

(c)
Notwithstanding anything to the contrary in this Subscription Agreement, Ignyte shall be entitled to delay the filing or effectiveness
of, or suspend the use of, the Registration Statement if it determines (i) that in order for the Registration Statement not to
contain a material misstatement or omission, (x) an amendment thereto would be needed to include information that would at that
time not otherwise be required in a current, quarterly, or annual report under the Exchange Act or (y) the negotiation or consummation
of a transaction by Ignyte or its subsidiaries is pending or an event has occurred, which negotiation, consummation or event Ignyte’s
board of directors reasonably believes would require additional disclosure by Ignyte in the Registration Statement of material
information that Ignyte has a bona fide business purpose for keeping confidential and the non-disclosure of which in the Registration
Statement would be expected, in the reasonable determination of Ignyte’s board of directors to cause the Registration Statement
to fail to comply with applicable disclosure requirements, or (ii) such delay or suspension arises out of, or is a result of,
or is related to or is in connection with the SEC Statement, Redeemable Share Classification Changes or other accounting matters,
or any related disclosure or other matters (each such circumstance, a “Suspension Event”); provided,
however, that Ignyte may not delay or suspend the Registration Statement on more than three occasions or for more than
ninety (90) consecutive calendar days, or more than one hundred and twenty (120) total calendar days in each case during any twelve-month
period. Upon receipt of any written notice from Ignyte of the happening of any Suspension Event during the period that the Registration
Statement is effective or if as a result of a Suspension Event the Registration Statement or related prospectus contains any untrue
statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements
therein (in light of the circumstances under which they were made, in the case of the prospectus) not misleading, the Investor
agrees that (i) it will immediately discontinue offers and sales of the Registrable Shares under the Registration Statement (excluding,
for the avoidance of doubt, sales conducted pursuant to Rule 144) until the Investor receives copies of a supplemental or amended
prospectus (which Ignyte agrees to promptly prepare) that corrects the misstatement(s) or omission(s) referred to above and receives
notice that any post-effective amendment has become effective or unless otherwise notified by Ignyte that it may resume such offers
and sales, and (ii) it will maintain the confidentiality of any information included in such written notice delivered by Ignyte
unless otherwise required by law or subpoena. If so directed by Ignyte, the Investor will deliver to Ignyte or, in the Investor’s
sole discretion destroy, all copies of the prospectus covering the Registrable Shares in the Investor’s possession; provided,
however, that this obligation to deliver or destroy all copies of the prospectus covering the Registrable Shares shall not
apply (A) to the extent Investor is required to retain a copy of such prospectus (1) in order to comply with applicable legal,
regulatory, self-regulatory or professional requirements or (2) in accordance with a bona fide pre-existing document retention
policy or (B) to copies stored electronically on archival servers as a result of automatic data back-up.

(d) Indemnification.

(i)
Ignyte agrees to indemnify, to the extent permitted by law, the Investor (to the extent a seller under the Registration Statement),
its directors, officers, partners, managers, members, stockholders, agents and each person who controls the Investor (within the
meaning of the Securities Act), to the extent permitted by law, against all losses, claims, damages, liabilities and reasonable
and documented out of pocket expenses (including reasonable and documented attorneys’ fees of one law firm) caused by any
untrue or alleged untrue statement of material fact contained in any Registration Statement, prospectus included in any Registration
Statement (“Prospectus”) or preliminary Prospectus or any amendment thereof or supplement thereto or any omission
or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case
of a Prospectus, in the light of the circumstances under which they were made) not misleading, except insofar as the same are
caused by or contained in any information or affidavit so furnished in writing to Ignyte by or on behalf of the Investor expressly
for use therein.

9

(ii)
In connection with any Registration Statement in which the Investor is participating, the Investor shall furnish (or cause to
be furnished) to Ignyte in writing such information and affidavits as Ignyte reasonably requests for use in connection with any
such Registration Statement or Prospectus and, to the extent permitted by law, shall indemnify Ignyte, its directors and officers
and each person or entity who controls Ignyte (within the meaning of the Securities Act) against any losses, claims, damages,
liabilities and expenses (including, without
limitation, reasonable outside attorneys’ fees) resulting from any untrue or alleged untrue statement of material fact contained
or incorporated by reference in any Registration Statement, Prospectus or preliminary Prospectus or any amendment thereof or supplement
thereto or any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements
therein (in the case of a Prospectus, in the light of the circumstances under which they were made) not misleading, but only to
the extent that such untrue statement or omission is contained (or not contained in, in the case of an omission) in any information
or affidavit so furnished in writing by or on behalf of the Investor expressly for use therein; provided, however,
that the liability of the Investor shall be several and not joint with any other investor and shall be limited to the net proceeds
received by the Investor from the sale of Registrable Shares giving rise to such indemnification obligation.

(iii)
Any person or entity entitled to indemnification herein shall (A) give prompt written notice to the indemnifying party of
any claim with respect to which it seeks indemnification (provided that the failure to give prompt notice shall not
impair any person’s or entity’s right to indemnification hereunder to the extent such failure has not prejudiced
the indemnifying party) and (B) unless in such indemnified party’s reasonable judgment a conflict of interest between
such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying party to assume the
defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the
indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without its consent
(but such consent shall not be unreasonably withheld). An indemnifying party who is not entitled to, or elects not to, assume
the defense of a claim shall not be obligated to pay the fees and expenses of more than one counsel for all parties
indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of legal counsel to any
indemnified party a conflict of interest exists between such indemnified party and any other of such indemnified parties with
respect to such claim. No indemnifying party shall, without the consent of the indemnified party, consent to the entry of any
judgment or enter into any settlement which cannot be settled in all respects by the payment of money (and such money is so
paid by the indemnifying party pursuant to the terms of such settlement) or which settlement includes a statement or
admission of fault and culpability on the part of such indemnified party or which does not include as an unconditional term
thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such
claim or litigation.

(iv)
The indemnification provided for under this Subscription Agreement shall remain in full force and effect regardless of any investigation
made by or on behalf of the indemnified party or any officer, director or controlling person or entity of such indemnified party
and shall survive the transfer of securities.

(v)
If the indemnification provided under this Section 8(d) from the indemnifying party is unavailable or insufficient
to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities and expenses referred to
herein, then the indemnifying party, in lieu of indemnifying the indemnified party, shall contribute to the amount paid or
payable by the indemnified party as a result of such losses, claims, damages, liabilities and expenses in such proportion as
is appropriate to reflect the relative fault of the indemnifying party and the indemnified party, as well as any other
relevant equitable considerations; provided, however, that the liability of the Investor shall be limited to
the net proceeds received by the Investor from the sale of Registrable Shares giving rise to such indemnification obligation.
The relative fault of the indemnifying party and indemnified party shall be determined by reference to, among other
things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or
alleged omission to state a material fact, was made by (or not made by, in the case of an omission), or relates to
information supplied by (or not supplied by, in the case of an omission), such indemnifying party or indemnified party, and
the indemnifying party’s and indemnified party’s relative intent, knowledge, access to information and
opportunity to correct or prevent such action. The amount paid or payable by a party as a result of the losses or other
liabilities referred to above shall be deemed to include, subject to the limitations set forth in Sections 8(d)(i), (ii) and (iii)
above, any legal or other fees, charges or expenses reasonably incurred by such party in connection with any investigation
or proceeding. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities
Act) shall be entitled to contribution pursuant to this Section 8(d)(v) from any person or entity who was not guilty
of such fraudulent misrepresentation.

(vi)
If the Shares acquired hereunder are either eligible to be sold (i) pursuant to an effective Registration Statement or (ii) without
restriction under, and without Ignyte being in compliance with the current public information requirements of, Rule 144 under
the Securities Act, then at the Investor’s request, Ignyte will reasonably
cooperate with Ignyte’s transfer agent, such that any remaining restrictive legend set forth on such Shares will be removed
in connection with a sale of such shares.

10

9. Termination.
This Subscription Agreement shall terminate and be void and of no further force and effect, and all rights and obligations of
the parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the
earliest to occur of (a) such date and time as the Transaction Agreement is terminated in accordance with its terms, (b) upon
the mutual written agreement of each of the parties hereto to terminate this Subscription Agreement, (c) if the conditions to
Closing set forth in Section 3 of this Subscription Agreement are not satisfied at, or are not capable of being
satisfied on or prior to, the Closing and, as a result thereof, the transactions contemplated by this Subscription Agreement
will not be or are not consummated at the Closing and (d) the Outside Date (as defined in the Transaction Agreement) if the
closing of the Transaction has not occurred on or before such date; provided that nothing herein will relieve any
party from liability for any willful breach hereof prior to the time of termination, and each party will be entitled to any
remedies at law or in equity to recover losses, liabilities or damages arising from any such willful breach. Ignyte shall
notify the Investor of the termination of the Transaction Agreement promptly after the termination of such agreement. Upon
the termination of this Subscription Agreement in accordance with this Section 9, any monies paid by the Investor to
Ignyte in connection herewith shall be promptly (and in any event within two (2) business days after such termination)
returned to the Investor.

10. Trust
Account Waiver. The Investor acknowledges that Ignyte is a blank check company with the powers and privileges to effect a
merger, asset acquisition, reorganization or similar business combination involving Ignyte and one or more businesses or
assets. The Investor further acknowledges that, as described in Ignyte’s prospectus relating to its initial public
offering dated January 27, 2021 (the “IPO Prospectus”) available at www.sec.gov, substantially all of
Ignyte’s assets consist of the cash proceeds of Ignyte’s initial public offering and private placement of its
securities, and substantially all of those proceeds have been deposited in a trust account (the “Trust
Account”) for the benefit of Ignyte, its public stockholders and the underwriter of Ignyte’s initial public
offering. Except with respect to interest earned on the funds held in the Trust Account that may be released to Ignyte to pay
its tax obligations, if any, the cash in the Trust Account may be disbursed only for the purposes set forth in the IPO
Prospectus. For and in consideration of Ignyte entering into this Subscription Agreement, the receipt and sufficiency of
which are hereby acknowledged, the Investor hereby irrevocably waives any and all right, title and interest, or any claim of
any kind it has or may have in the future, in or to any monies held in the Trust Account, and agrees not to seek recourse
against the Trust Account as a result of, or arising out of, this Subscription Agreement; provided, that nothing in
this Section 10 shall be deemed to limit the Investor’s right, title, interest or claim to the Trust Account by
virtue of the Investor’s record or beneficial ownership of Ignyte Common Stock acquired by any means other than
pursuant to this Subscription Agreement.

11. Miscellaneous.

(a)
Neither this Subscription Agreement nor any rights that may accrue to the Investor hereunder (other than the Shares acquired hereunder,
if any) may be transferred or assigned, other than an assignment to any fund or account managed by the same investment manager
as the Investor or an affiliate thereof, subject to, if such transfer or assignment is prior to the Closing, such transferee or
assignee, as applicable, executing a joinder to this Subscription Agreement or a separate subscription agreement in substantially
the same form as this Subscription Agreement, including with respect to the Subscription Amount and other terms and conditions,
provided, that, in the case of any such transfer or assignment, the initial party to this Subscription Agreement shall
remain bound by its obligations under this Subscription Agreement in the event that the transferee or assignee, as applicable,
does not comply with its obligations to consummate the purchase of Shares contemplated hereby. Neither this Subscription Agreement
nor any rights that may accrue to Ignyte hereunder or any of Ignyte’s obligations may be transferred or assigned other than
pursuant to the Transaction.

(b)
Ignyte may request from the Investor such additional information as Ignyte may deem necessary to evaluate the eligibility of the
Investor to acquire the Shares and in connection with the inclusion of the Shares in the Registration Statement, and the Investor
shall provide such information as may reasonably be requested, to the extent readily available and to the extent consistent with
its internal policies and procedures. The Investor acknowledges that Ignyte may file a form of this Subscription Agreement with
the SEC as an exhibit to a current or periodic report or a registration statement of Ignyte.

11

(c)
The Investor acknowledges that Ignyte will rely on the acknowledgments, understandings, agreements, representations and warranties
of the Investor contained in this Subscription Agreement. Prior to the Closing, the Investor agrees to promptly notify Ignyte
if any of the acknowledgments, understandings, agreements, representations and warranties of the Investor set forth herein are
no longer accurate.

(d)
Ignyte and the Investor are each entitled to rely upon this Subscription Agreement and each is irrevocably authorized to produce
this Subscription Agreement or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry
with respect to the matters covered hereby.

(e)
All of the representations and warranties contained in this Subscription Agreement shall survive the Closing. All of the covenants
and agreements made by each party hereto in this Subscription Agreement shall survive the Closing until the applicable statute
of limitations or in accordance with their respective terms, if a shorter period.

(f)
This Subscription Agreement may not be modified, waived or terminated (other than pursuant to the terms of Section 9
above) except by an instrument in writing, signed by each of the parties hereto and, to the extent required by the
Transaction Agreement, the Company. No failure or delay of either party in exercising any right or remedy hereunder shall
operate as a waiver thereof, nor shall any single or partial exercise of any such right or power, or any abandonment or
discontinuance of steps to enforce such right or power, or any course of conduct, preclude any other or further exercise
thereof or the exercise of any other right or power. The rights and remedies of the parties and third-party beneficiaries
hereunder are cumulative and are not exclusive of any rights or remedies that they would otherwise have hereunder.

(g)
This Subscription Agreement (including the schedule hereto) constitutes the entire agreement, and supersedes all other prior
agreements, understandings, representations and warranties, both written and oral, among the parties, with respect to the
subject matter hereof. Except as set forth in Section 8(d), Section 11(c) and Section 11(d) with respect to the
persons referenced therein, this Subscription Agreement shall not confer any rights or remedies upon any person other than
the parties hereto, and their respective successor and assigns.

(h)
Except as otherwise provided herein, this Subscription Agreement shall be binding upon, and inure to the benefit of the parties
hereto and their heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements,
representations, warranties, covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon,
such heirs, executors, administrators, successors, legal representatives and permitted assigns.

(i)
If any provision of this Subscription Agreement shall be adjudicated by a court of competent jurisdiction to be invalid, illegal
or unenforceable, the validity, legality or enforceability of the remaining provisions of this Subscription Agreement shall not
in any way be affected or impaired thereby and shall continue in full force and effect.

(j)
Each party shall pay all of its own costs and expenses incurred in anticipation of, relating to and in connection with the negotiation
and execution of this Subscription Agreement and the transactions contemplated hereby, whether or not such transactions are consummated.

(k)
This Subscription Agreement may be executed in one or more counterparts (including by electronic mail or in .pdf) and by different
parties in separate counterparts, with the same effect as if all parties hereto had signed the same document. All counterparts
so executed and delivered shall be construed together and shall constitute one and the same agreement.

(l)
The parties hereto acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Subscription
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that
the parties shall be entitled to an injunction or injunctions to prevent breaches of this Subscription Agreement, without posting
a bond or undertaking and without proof of damages, to enforce specifically the terms and provisions of this Subscription Agreement,
this being in addition to any other remedy to which such party is entitled at law, in equity, in contract, in tort or otherwise.

12

(m)
THE PARTIES HERETO IRREVOCABLY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE COURT OF CHANCERY OF THE STATE OF DELAWARE (OR,
TO THE EXTENT SUCH COURT DOES NOT HAVE SUBJECT MATTER JURISDICTION, THE SUPERIOR COURT OF THE STATE OF DELAWARE, OR THE
UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE) SOLELY IN RESPECT OF THE INTERPRETATION AND ENFORCEMENT OF THE
PROVISIONS OF THIS SUBSCRIPTION AGREEMENT AND THE DOCUMENTS REFERRED TO IN THIS SUBSCRIPTION AGREEMENT AND IN RESPECT OF THE
TRANSACTIONS CONTEMPLATED HEREBY, AND HEREBY WAIVE, AND AGREE NOT TO ASSERT, AS A DEFENSE IN ANY ACTION, SUIT OR PROCEEDING
FOR INTERPRETATION OR ENFORCEMENT HEREOF OR ANY SUCH DOCUMENT THAT IS NOT SUBJECT THERETO OR THAT SUCH ACTION, SUIT OR
PROCEEDING MAY NOT BE BROUGHT OR IS NOT MAINTAINABLE IN SAID COURTS OR THAT VENUE THEREOF MAY NOT BE APPROPRIATE OR THAT THIS
SUBSCRIPTION AGREEMENT OR ANY SUCH DOCUMENT MAY NOT BE ENFORCED IN OR BY SUCH COURTS, AND THE PARTIES HERETO IRREVOCABLY
AGREE THAT ALL CLAIMS WITH RESPECT TO SUCH ACTION, SUIT OR PROCEEDING SHALL BE HEARD AND DETERMINED BY SUCH A DELAWARE STATE
OR FEDERAL COURT. THE PARTIES HEREBY CONSENT TO AND GRANT ANY SUCH COURT JURISDICTION OVER THE PERSON OF SUCH PARTIES AND
OVER THE SUBJECT MATTER OF SUCH DISPUTE AND AGREE THAT MAILING OF PROCESS OR OTHER PAPERS IN CONNECTION WITH SUCH ACTION,
SUIT OR PROCEEDING IN THE MANNER PROVIDED IN THIS SECTION 11(m) OF THIS SUBSCRIPTION AGREEMENT OR IN SUCH OTHER MANNER
AS MAY BE PERMITTED BY LAW SHALL BE VALID AND SUFFICIENT SERVICE THEREOF. THIS SUBSCRIPTION AGREEMENT SHALL BE GOVERNED BY,
AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS
THAT WOULD OTHERWISE REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER STATE.

(n)
EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS SUBSCRIPTION AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND
UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING
OUT OF OR RELATING TO THIS SUBSCRIPTION AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS SUBSCRIPTION AGREEMENT. EACH PARTY
CERTIFIES AND ACKNOWLEDGES THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE,
THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER; (II) SUCH PARTY UNDERSTANDS
AND HAS CONSIDERED THE IMPLICATIONS OF THE FOREGOING WAIVER; (III) SUCH PARTY MAKES THE FOREGOING WAIVER VOLUNTARILY; AND (IV)
SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS SUBSCRIPTION AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS
IN THIS SECTION 11(n).

12. Non-Reliance
and Exculpation. The Investor acknowledges that it is not relying upon, and has not relied upon, any
statement, representation or warranty made by any person, firm or corporation (including, without limitation, Ignyte and any
of its affiliates, any control persons, officers, directors, employees, partners, agents, representatives, legal counsel,
financial advisors or accountants), other than the statements, representations and warranties of Ignyte expressly contained
in Section 5 of this Subscription Agreement, in making its investment or decision to invest in Ignyte. The Investor
acknowledges and agrees that none of (i) the Other Investors pursuant to this Subscription Agreement or any Other
Subscription Agreement related to the private placement of the Shares (including the Other Investors’ respective
affiliates or any control persons, officers, directors, employees, partners, agents or representatives of any of the
foregoing), (ii) any other party to the Transaction Agreement (other than Ignyte), or (iii) any affiliates, or any control
persons, officers, directors, employees, partners, agents or representatives of any of Ignyte, the Company or any other party
to the Transaction Agreement shall be liable to the Investor, or to any Other Investor, pursuant to this Subscription
Agreement or any Other Subscription Agreement related to the private placement of the Shares, the negotiation hereof or
thereof or the subject matter hereof or thereof, or the transactions contemplated hereby or thereby, for any action
heretofore or hereafter taken or omitted to be taken by any of them in connection with the purchase of the Shares.

13

13. Press
Releases. Ignyte shall, by 9:00 a.m., New York City time, on the first business day immediately following the date of
this Subscription Agreement, issue one or more press releases or furnish or file with the SEC a Current Report on Form
8-K (collectively, the “Disclosure Document”) disclosing, to the extent not previously publicly disclosed,
the PIPE Investment (as defined in the Transaction Agreement), all material terms of the Transaction and any other material,
non-public information that Ignyte, or any of its officers, employees or agents on behalf of Ignyte, has provided to the
Investor at any time prior to the filing of the Disclosure Document. From and after the disclosure of the Disclosure
Document, the Investor shall no longer be subject to any confidentiality or similar obligations under any current agreement,
whether written or oral, with Ignyte or any of its affiliates, and, to the knowledge of Ignyte, the Investor shall not be in
possession of any material, non-public information received from Ignyte or any of its officers, directors, employees or
agents. All press releases or other public communications relating to the transactions contemplated hereby between Ignyte and
the Investor, and the method of the release for publication thereof, shall be subject to the prior approval of (i) Ignyte,
and (ii) the Investor to the extent such press release or public communication references the Investor or its affiliates or
investment advisers by name or any trademark owned by the Investor, its affiliates or its investment advisers. The
restriction in this Section 13 shall not apply to the extent the public announcement is required by applicable
securities law, any governmental authority or stock exchange rule; provided, that in such an event, the applicable
party shall use its commercially reasonable efforts to consult with the other party in advance as to its form, content and
timing.

14.
Notices. All notices and other communications among the parties shall be in writing and shall be deemed to have been duly
given (i) when delivered in person, (ii) when delivered after posting in the United States mail having been sent registered or
certified mail return receipt requested, postage prepaid, (iii) when delivered by FedEx or other nationally recognized overnight
delivery service, or (iv) when delivered by email (in each case in this clause (iv), solely if receipt is confirmed, but excluding
any automated reply, such as an out-of-office notification), addressed as follows:

If to the
Investor, to the address provided on the Investor’s signature page hereto.

If to Ignyte,
to:

Ignyte Acquisition Corp.

640 Fifth Avenue 

New York, New York 10019

Attention: David Rosenberg, Co-Chief Executive
Officer

                David J. Strupp, Jr., Co-Chief Executive Officer

Email:      drosenberg@ignytespac.com 

                dstrupp@ignytespac.com

with copies
to (which shall not constitute notice), to:

DLA Piper LLP’ (US) 

51 John F. Kennedy Parkway 

Suite 120 

Short Hills, NJ 0708 

Attention:
Andrew P. Gilbert

                 Scott
A. Cowan

Email:       andrew.gilbert@us.dlapiper.com

           scott.cowan@us.dlapiper.com

If to Company, to:

Peak Bio
Co., Ltd. 

Building B #1009

670 Daewangpangyo-ro
(Sampyeong-dong, U Space 2), 

Bundang-gu, Seongnam-si, Gyenggi-do 13494 

Attention: Hoyoung Huh, Chief Executive Officer

Email:       hoyoung.huh@ph-pharma.com

14

with copies to (which shall not constitute notice), to:

BC Burr
McCabe Law 

584 Castro Street #882 

San Francisco, CA 94114 

Attention: Peter McCabe 

Email: pmccabe@bcbmlaw.com

or to such
other address or addresses as the parties may from time to time designate in writing. Copies delivered solely to outside counsel
shall not constitute notice.

SIGNATURE
PAGES FOLLOW

15

IN
WITNESS WHEREOF, the Investor has executed or caused this Subscription Agreement to be executed by its duly authorized representative
as of the date first set forth above.

	 	State/Country of Formation or Domicile:
	Name of Investor:	 
	By:	 
	Name:	 
	Title:	 
	Name in which Shares are to be registered (if different):	 
	Investor’s EIN:	 
	Business Address-Street:	Mailing Address-Street (if different):
	City, State, Zip:	City, State, Zip:
	Attn:	Attn:
	Telephone No.:	Telephone No.:
	Facsimile No.:	Facsimile No.:
	Number of Shares subscribed for:	 
	Aggregate Subscription Amount: $	Price Per Share: $10.00

You
must pay the Subscription Amount by wire transfer of United States dollars in immediately available funds to the account specified
by Ignyte in the Closing Notice.

Signature
Page to Subscription Agreement

IN
WITNESS WHEREOF, Ignyte has accepted this Subscription Agreement as of the date first set forth above.

	 	IGNYTE ACQUISITION CORP.
	 	 
	 	By 	         	 
	 	NAME: 
	 	TITLE:

Signature
Page to Subscription AgreementExhibit 10.2

KEY
COMPANY STOCKHOLDER FORWARD PURCHASE AGREEMENT

This
KEY COMPANY STOCKHOLDER FORWARD PURCHASE AGREEMENT (this “Purchase Agreement”) is entered into on April 28,
2022, by and between Ignyte Acquisition Corp., a Delaware corporation (“Ignyte”), and the undersigned subscriber
(the “Investor”).

WHEREAS,
this Purchase Agreement is being entered into in connection with the Business Combination Agreement, dated as of the date hereof
(as may be amended, supplemented or otherwise modified from time to time, the “Transaction Agreement”), by
and between Ignyte, Ignyte Korea Co., Ltd., a corporation organized under the laws of the Republic of Korea (“Merger
Sub”) and Peak Bio Co., Ltd., a corporation organized under the laws of the Republic of Korea (the “Company,”
and together with Ignyte and Merger Sub, the “Parties”), pursuant to which, among other things, the Parties
desire to enter into a business combination transaction (such transaction, together with the other transactions contemplated by,
and subject to the terms and conditions of, the Transaction Agreement, collectively, the “Transaction”) structured
as a comprehensive share swap whereby (i) the stockholders of the Company will transfer their respective shares of common stock
of the Company, par value KRW 500 per share (the “Company Common Stock”), to Merger Sub in exchange for shares
of common stock of Ignyte, par value $0.0001 per share (the “Ignyte Common Stock”) held by Merger Sub, and
(ii) in the course of such share swap, Merger Sub will contribute the shares of Company Common Stock to Ignyte in consideration
of Ignyte Common Stock (which will in-turn be distributed to the stockholders of the Company as described in (i) above);

WHEREAS,
in connection with the Transaction, Ignyte is seeking commitments from interested investors to purchase shares of Ignyte Common
Stock (the “Shares”), in a private placement for a purchase price of $10.00 per share (the “Per Share
Subscription Price”);

WHEREAS,
substantially concurrently with the execution of this Purchase Agreement, Ignyte is entering into separate subscription agreements
with certain investors, and subsequent to the date hereof but prior to the consummation of the Transaction, Ignyte may enter into
additional subscription agreements with certain additional investors (collectively, the “Other Investors”);
and

WHEREAS,
in the event the aggregate purchase price of the Other Investors is less than $30,000,000 as of the date that is five (5) business
days prior to the Transaction Closing Date (as defined below) (the “Other Investors’ Aggregate PIPE Investment
Amount”) and subject to the satisfaction of certain conditions specified below, the Investor will purchase Shares with
an aggregate purchase price equal to the lesser of (i) $10,000,000 and (ii) the amount by which the Other Investors’ Aggregate
PIPE Investment Amount is less than $30,000,000 (the “Subscription Amount”).

NOW,
THEREFORE, in consideration of the foregoing and the mutual representations, warranties and covenants, and subject to the conditions,
set forth herein, and intending to be legally bound hereby, each of the Investor and Ignyte acknowledges and agrees as follows:

1. Subscription.
Subject to the satisfaction of the conditions to Closing set forth in Section 3 below, in the event the
Other Investors’ Aggregate PIPE Investment Amount is less than $30,000,000 as of the date that is five (5) business
days prior to the Transaction Closing Date (as defined below) and subject to the satisfaction of the closing conditions
specified below, including but not limited to securing the Margin Loan (as defined below), the Investor hereby irrevocably
subscribes for and agrees to purchase from Ignyte, and Ignyte agrees to issue and sell to the Investor, the number of Shares
determined by dividing the Investor Forward Subscription Amount by the Per Share Purchase Price, on the terms and subject to
the conditions provided for herein.

2. Closing. The closing of the sale of the Shares contemplated hereby (the “Closing”)
shall occur on a closing date (the “Closing Date”) specified in the Closing Notice (as defined below), and
the Closing shall be conditioned upon the prior or substantially concurrent consummation of the Transaction and satisfaction
of the conditions set forth above and below (the closing date of the Transaction, the “Transaction
Closing Date”). Upon delivery of written notice from (or on behalf of) Ignyte to the Investor (the
“Closing Notice”), that Ignyte reasonably expects all conditions to the closing of the Transaction to be
satisfied or waived on an expected Transaction Closing Date that is not less than five (5) business days from the date on
which the Closing Notice is delivered to the Investor, the Investor shall deliver the Subscription Amount three (3) business
days prior to the expected Closing Date by wire transfer of United States dollars in immediately available funds to the
account(s) specified by Ignyte in the Closing Notice. On the Closing Date, Ignyte shall issue the Shares to the Investor and
subsequently cause the Shares to be registered in book entry form in the name of the Investor and will provide to the
Investor, upon request by the Investor, evidence of such issuance from Ignyte’s transfer agent. For purposes of this
Purchase Agreement, “business day” shall mean a day, other than a Saturday, Sunday or other day on which
commercial banks in New York, New York are authorized or required by law to close. Prior to or at the Closing, the Investor
shall deliver to Ignyte a duly completed and executed Internal Revenue Service Form W-9 or appropriate Form W-8. In the event
the Transaction Closing Date does not occur within two (2) business days after the Closing Date under this Purchase
Agreement, Ignyte shall promptly (but not later than two (2) business days thereafter) return the Subscription Amount to the
Investor by wire transfer of U.S. dollars in immediately available funds to the account specified by the Investor, and any
book-entries for the Shares shall be deemed cancelled; provided that, unless this Purchase Agreement has been
terminated pursuant to Section 9 hereof, such return of funds shall not terminate this Purchase Agreement or relieve
the Investor of its obligation to purchase the Shares at the Closing in the event Ignyte delivers a subsequent Closing Notice
in accordance with this Section 2.

3. Closing Conditions. The obligation of the parties hereto to consummate the purchase and sale of the Shares pursuant to
this Purchase Agreement is subject to the following conditions: (a) there shall not be in force any injunction or order enjoining
or prohibiting the issuance and sale of the Shares under this Purchase Agreement; (b) except to the extent consented to in writing
by the Investor, no amendments of, or waivers under, the Transaction Agreement (as the same exists as of the date of this Purchase
Agreement) (including the conditions thereto) shall have occurred that materially and adversely affect the economic benefits the
Investor (in its capacity as such) would reasonably expect to receive under this Purchase Agreement; (c)(i) solely with respect
to the Investor’s obligation to close, the representations and warranties made by Ignyte, and (ii) solely with respect to
the Ignyte’s obligation to close, the representations and warranties made by the Investor, in each case, in this Purchase
Agreement shall be true and correct in all material respects as of the Closing Date other than (x) those representations and warranties
qualified by materiality, Material Adverse Effect (as defined below) or similar qualification, which shall be true and correct
in all respects as of the Closing Date and (y) those representations and warranties expressly made as of an earlier date, which
shall be true and correct in all material respects (or, if qualified by materiality, Material Adverse Effect or similar qualification,
all respects) as of such date, in each case without giving effect to the consummation of the Transaction; and (d) the Investor
shall have received margin financing from a lender reasonably acceptable to Ignyte and Investor in the aggregate amount of the
Subscription Amount (the “Margin Loan”) within 180 days of the closing of the transactions contemplated by
the Transaction Agreement (the “Margin Period”).

4. Further Assurances.

(a) At the Closing, the parties hereto shall execute and deliver such additional documents and take such additional actions as the
parties reasonably may deem to be practical and necessary in order to consummate the subscription as contemplated by this Purchase
Agreement.

(b) In order to satisfy the obligations under this Purchase Agreement, the Investor shall use reasonable best efforts to take,
or cause to be taken, all necessary and proper actions to ensure the receipt of the Margin Loan by the Investor within the Margin
Period.

5. Ignyte Representations and Warranties. Ignyte represents and warrants to the Investor that:

(c) Ignyte was duly incorporated and is validly existing and in good standing under the laws of the State of Delaware. Ignyte has
all power (corporate or otherwise) and authority to own, lease and operate its properties and conduct its business as presently
conducted and to enter into, deliver and perform its obligations under this Purchase Agreement.

(d)
As of the Closing Date, the Shares will be duly authorized and, when issued and delivered to the Investor against full
payment therefor in accordance with the terms of this Purchase Agreement, the Shares will be validly issued, fully paid and
non-assessable and will not have been issued in violation of or subject to any preemptive or similar rights created under
Ignyte’s organizational documents (as in effect at such time of issuance) or under the Delaware General Corporation
Law.

2

(e) This Purchase Agreement has been duly authorized, executed and delivered by Ignyte and, assuming that this Purchase Agreement
constitutes the valid and binding agreement of the Investor, this Purchase Agreement is enforceable against Ignyte in accordance
with its terms, except as may be limited or otherwise affected by (i) bankruptcy, insolvency, fraudulent conveyance, reorganization,
moratorium or other laws relating to or affecting the rights of creditors generally, or (ii) principles of equity, whether considered
at law or equity.

(f) The issuance and sale by Ignyte of the Shares pursuant to this Purchase Agreement will not (i) conflict with or result in a breach
or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any
lien, charge or encumbrance upon any of the property or assets of Ignyte or any of its subsidiaries pursuant to the terms of any
indenture, mortgage, deed of trust, loan agreement, lease, license or other agreement or instrument to which Ignyte or any of
its subsidiaries is a party or by which Ignyte or any of its subsidiaries is bound or to which any of the property or assets of
Ignyte is subject that would reasonably be expected to have a material adverse effect on the business, financial condition or
results of operations of Ignyte and its subsidiaries, taken as a whole (a “Material Adverse Effect”), or materially
and adversely affect the validity of the Shares or the legal authority of Ignyte to comply in all material respects with its obligations
under this Purchase Agreement; (ii) result in any violation of the provisions of the organizational documents of Ignyte; or (iii)
result in any violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body,
domestic or foreign, having jurisdiction over Ignyte or any of its properties that would reasonably be expected to have a Material
Adverse Effect or materially and adversely affect the validity of the Shares or the legal authority of Ignyte to comply in all
material respects with its obligations under this Purchase Agreement.

(g) As of their respective filing dates, or, if amended, as of the date of such amendment, which shall be deemed to supersede such
original filing, all reports required to be filed by Ignyte with the U.S. Securities and Exchange Commission (the “SEC”)
since January 28, 2021 (the “SEC Reports”) complied in all material respects with the applicable requirements
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations of the
SEC promulgated thereunder. None of the SEC Reports filed under the Exchange Act included, when filed or, if amended, as of the
date of such amendment with respect to those disclosures that are amended, any untrue statement of a material fact or omitted
to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made,
not misleading; provided, that Ignyte makes no such representation or warranty with respect to any registration statement or any
proxy statement/prospectus to be filed by Ignyte with respect to the Transaction or any other information relating to the Company
or any of its affiliates Ignyte included in any SEC Report or filed as an exhibit thereto. Ignyte has timely filed with the SEC
each SEC Report that Ignyte was required to file with the SEC. As of the date hereof, there are no material outstanding or unresolved
comments in comment letters received by Ignyte from the staff of the Division of Corporation Finance of the SEC with respect to
any of the SEC Reports. Notwithstanding the foregoing, this representation and warranty shall not apply to any statement or information
in the SEC Reports that relates to (i) the topics referenced in the SEC’s “Staff Statement on Accounting and Reporting
Considerations for Warrants Issued by Special Purpose Acquisition Companies” on April 12, 2021 or any subsequent guidance,
statements or interpretations issued by the SEC or the Staff (collectively, the “SEC Statement”) or (ii) the Company’s
outstanding redeemable shares as temporary, as opposed to permanent, equity (“Redeemable Share Classification Changes”).
Neither any correction, amendment or restatement of Ignyte’s financial statements due to the SEC Statement, Redeemable Share
Classification Changes or to other accounting matters related to initial public offering securities or expenses, nor any changes
in accounting or disclosure related thereto, shall be deemed to be a breach of any representation or warranty by Ignyte.

(h) Ignyte is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or
registration with, any court or other federal, state, local or other governmental authority, self-regulatory organization or
other person in connection with the issuance of the Shares pursuant to this Purchase Agreement, other than (i) filings with
the SEC, (ii) in connection with or as a result of the SEC Statement or Redeemable Share Classification Changes, (iii)
filings required by applicable state securities laws, (iv) the filings required in accordance with Section 13 of this
Purchase Agreement; (v) those required by the New York Stock Exchange or Nasdaq, as applicable, including with respect to
obtaining approval of Ignyte’s stockholders, (vi) the filing of a notification under the Hart-Scott-Rodino Antitrust
Improvements Act of 1976, if applicable, and (vii) the failure of which to obtain would not be reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect.

3

(i)
As of the date hereof, Ignyte has not received any written communication from a governmental authority that alleges that
Ignyte is not in compliance with or is in default or violation of any applicable law, except where such
non-compliance, default or violation would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect.

(j)
Assuming the accuracy of the Investor’s representations and warranties set forth in Section 6 of this Purchase
Agreement, no registration under the Securities Act of 1933, as amended (the “Securities Act”), is
required for the offer and sale of the Shares by Ignyte to the Investor.

(k)
Neither Ignyte nor any person acting on its behalf has offered or sold the Shares by any form of general solicitation or
general advertising in violation of the Securities Act.

(l)
As of the date hereof, the issued and outstanding shares of Ignyte Common Stock are registered pursuant to Section
12(b) of the Exchange Act and are listed for trading on Nasdaq. There is no suit, action, proceeding or investigation pending
or, to the knowledge of Ignyte, threatened against Ignyte by Nasdaq or the SEC with respect to any intention by such entity
to deregister the Shares or prohibit or terminate the listing of the Shares on Nasdaq, excluding, for the purposes of
clarity, the customary ongoing review by Nasdaq in connection with the Transaction. Ignyte has taken no action that is
designed to terminate the registration of the Shares under the Exchange Act prior to the Closing.

(m)
Ignyte is not under any obligation to pay any broker’s fee or commission in connection with the sale of the
Shares.

(n)
The Other Subscription Agreements reflect the same Per Share Subscription Price and other terms with respect to the purchase of
the Shares that are not materially more favorable to such Other Investor thereunder than the terms of this Purchase Agreement,
other than terms particular to the regulatory requirements of such Other Investor or its affiliates or related funds.

6. Investor Representations and Warranties. The Investor represents and warrants to Ignyte that:

(a)
The Investor (i) is a “qualified institutional buyer” (as defined in Rule 144A under the Securities Act) or an
“accredited investor” (within the meaning of Rule 501(a) under the Securities Act), in each case, satisfying the
applicable requirements set forth on Schedule A, (ii) is acquiring the Shares only for its own account and not for the
account of others, or if the Investor is subscribing for the Shares as a fiduciary or agent for one or more investor
accounts, each owner of such account is a “qualified institutional buyer” (as defined in Rule 144A under the
Securities Act) or an “accredited investor” (within the meaning of Rule 501(a) under the Securities Act) and the
Investor has full investment discretion with respect to each such account, and the full power and authority to make the
acknowledgements, representations and agreements herein on behalf of each owner of each such account, and (iii) is not
acquiring the Shares with a view to, or for offer or sale in connection with, any distribution thereof in violation of the
Securities Act or the laws of any jurisdiction (and shall provide the requested information set forth on Schedule
A).

(b) The Investor acknowledges and agrees that the Shares are being offered in a transaction not involving any public offering
within the meaning of the Securities Act, that the Shares have not been registered under the Securities Act and that Ignyte
is not required to register the Shares except as set forth in Section 8 of this Purchase Agreement. The Investor
acknowledges and agrees that the Shares may not be offered, resold, transferred, pledged or otherwise disposed of by the
Investor absent an effective registration statement under the Securities Act except (i) to Ignyte or a subsidiary thereof,
(ii) to non-U.S. persons pursuant to offers and sales that occur outside the United States within the meaning of Regulation S
under the Securities Act or (iii) pursuant to Rule 144 under the Securities Act or another applicable exemption from the
registration requirements of the Securities Act, and, in each case, in accordance with any applicable securities laws of the
states of the United States and other applicable jurisdictions, and that any certificates or book entries representing the
Shares shall contain a restrictive legend to such effect. The Investor acknowledges and agrees that the Shares will be
subject to the foregoing transfer restrictions and, as a result of these transfer restrictions, the Investor may not be able
to readily offer, resell, transfer, pledge or otherwise dispose of the Shares and may be required to bear the financial risk
of an investment in the Shares for an indefinite period of time. The Investor acknowledges and agrees that the Shares will
not immediately be eligible for offer,
resale, transfer, pledge or disposition pursuant to Rule 144 promulgated under the Securities Act, and that the provisions of
Rule 144(i) will apply to the Shares. The Investor acknowledges and agrees that it has been advised to consult legal, tax and
accounting advisors prior to making any offer, resale, transfer, pledge or disposition of any of the Shares.

4

(c) The Investor acknowledges and agrees that the Investor is purchasing the Shares from Ignyte. The Investor further acknowledges
that there have been no representations, warranties, covenants and agreements made to the Investor by or on behalf of Ignyte,
the Company, any of their respective affiliates or any control persons, officers, directors, employees, agents or representatives
of any of the foregoing or any other person or entity, expressly or by implication, other than those representations, warranties,
covenants and agreements of Ignyte expressly set forth in Section 5 of this Purchase Agreement.

(d)
The Investor acknowledges and agrees that the Investor has received such information as the Investor deems necessary in
order to make an investment decision with respect to the Shares, including, with respect to Ignyte, the Transaction and the
business of the Company and its subsidiaries. Without limiting the generality of the foregoing, the Investor acknowledges
that it has reviewed Ignyte’s filings with the SEC. The Investor acknowledges and agrees that the Investor and the
Investor’s professional advisor(s), if any, have had the full opportunity to ask such questions, receive such answers
and obtain such information as the Investor and the Investor’s professional advisor(s), if any, have deemed necessary
to make an investment decision with respect to the Shares.

(e)
The Investor became aware of this offering of the Shares solely by means of direct contact between the Investor and
Ignyte, the Company or a representative of Ignyte or the Company, and the Shares were offered to the Investor solely by
direct contact between the Investor and Ignyte, the Company or a representative of Ignyte or the Company. The Investor did
not become aware of this offering of the Shares, nor were the Shares offered to the Investor, by any other means. The
Investor acknowledges that the Shares (i) were not offered by any form of general solicitation or general advertising and
(ii) are not being offered in a manner involving a public offering under, or in a distribution in violation of, the
Securities Act, or any state securities laws. The Investor acknowledges that there have not been, and the Investor hereby
agrees that it is not relying upon, and has not relied upon, any statement, covenant, agreement, representation or warranty
made by any person, firm or corporation (including, without limitation, Ignyte, the Company, any of their respective
affiliates or any control persons, officers, directors, employees, agents, representatives, legal counsel, financial advisors
or accountants of any of the foregoing), other than the representations and warranties of Ignyte contained in Section
5 of this Purchase Agreement, in making its investment or decision to invest in Ignyte.

(f) The Investor acknowledges that it is aware that there are substantial risks incident to the purchase and ownership of the
Shares, including those set forth in Ignyte’s filings with the SEC. The Investor has such knowledge and experience in financial
and business matters as to be capable of evaluating the merits and risks of an investment in the Shares, and the Investor has
sought such accounting, legal and tax advice as the Investor has considered necessary to make an informed investment decision.
The Investor acknowledges that the Investor shall be responsible for any of the Investor’s tax liabilities that may arise
as a result of the transactions contemplated by this Purchase Agreement, and that neither Ignyte nor the Company has provided
any tax advice or any other representation or guarantee regarding the tax consequences of the transactions contemplated by the
Purchase Agreement.

(g)
Alone, or together with any professional advisor(s), the Investor has adequately analyzed and fully considered the risks of an
investment in the Shares and determined that the Shares are a suitable investment for the Investor and that the Investor is able
at this time and in the foreseeable future to bear the economic risk of a total loss of the Investor’s investment in Ignyte.
The Investor acknowledges specifically that a possibility of total loss exists.

(h)
In making its decision to purchase the Shares, the Investor has relied solely upon independent investigation made by the Investor
and the representations and warranties of Ignyte in Section 5.

(i)
The Investor acknowledges and agrees that no federal or state agency has passed upon or endorsed the merits of the
offering of the Shares or made any findings or determination as to the fairness of this investment.

5

(j)
The Investor has been duly formed or incorporated and is validly existing and is in good standing under the laws of its
jurisdiction of formation or incorporation, with power and authority to enter into, deliver and perform its obligations under
this Purchase Agreement.

(k)
The execution, delivery and performance by the Investor of this Purchase Agreement, the purchase of the Shares
hereunder, the compliance by the Investor with all of the provisions of this Purchase Agreement and the consummation of the
transactions contemplated herein are within the powers of the Investor, have been duly authorized and will not constitute or
result in a breach, violation or default, conflict with or result in the creation or imposition of any lien, charge or
encumbrance upon any of the property or assets of the Investor pursuant to the terms of (a) any order, ruling or regulation
of any court or other tribunal or of any governmental commission or agency, (b) any indenture, mortgage, deed of trust, loan
agreement, lease, license or other agreement or undertaking, to which the Investor is a party, by which the Investor is bound
or to which any of the property or assets of the Investor is subject, and (c) if the Investor is not an individual, the
Investor’s organizational documents, including, without limitation, its incorporation or formation papers, bylaws,
indenture of trust or partnership or operating agreement, as may be applicable. The signature of the Investor on this
Purchase Agreement is genuine, and the signatory has legal competence and capacity to execute the same or the signatory has
been duly authorized to execute the same, and, assuming that this Purchase Agreement constitutes the valid and binding
agreement of Ignyte, this Purchase Agreement constitutes a legal, valid and binding obligation of the Investor, enforceable
against the Investor in accordance with its terms except as may be limited or otherwise affected by (i) bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium or other laws relating to or affecting the rights of creditors
generally, and (ii) principles of equity, whether considered at law or equity.

(l)
Neither the Investor nor, if the Investor is not an individual, any of its officers, directors, managers, managing members,
general partners or any other person acting in a similar capacity or carrying out a similar function, is (i) a person named
on the Specially Designated Nationals and Blocked Persons List, the Foreign Sanctions Evaders List, the Sectoral Sanctions
Identification List, or any other similar list of sanctioned persons administered by the U.S. Treasury Department’s
Office of Foreign Assets Control (“OFAC”), or any similar list of sanctioned persons administered by the
European Union or any individual European Union member state, including the United Kingdom (collectively, “Sanctions
Lists”); (ii) directly or indirectly owned or controlled by, or acting on behalf of, one or more persons on a
Sanctions List; (iii) organized, incorporated, established, located or resident, or a citizen, national, or the government,
including any political subdivision, agency, or instrumentality thereof, of, Cuba, Iran, North Korea, Syria, Venezuela, the
Crimea region of Ukraine, or any other country or territory embargoed or subject to substantial trade restrictions by the
United States, the European Union or any individual European Union member state, including the United Kingdom; (iv) a
Designated National as defined in the Cuban Assets Control Regulations, 31 C.F.R. Part 515; or (v) a non-U.S. shell bank or
providing banking services indirectly to a non-U.S. shell bank (collectively, a “Prohibited Investor”).
The Investor represents that if it is a financial institution subject to the Bank Secrecy Act (31 U.S.C. Section 5311 et
seq.) (the “BSA”), as amended by the USA PATRIOT Act of 2001 (the “PATRIOT Act”), and
its implementing regulations (collectively, the “BSA/PATRIOT Act”), that the Investor maintains policies
and procedures reasonably designed to comply with applicable obligations under the BSA/PATRIOT Act. The Investor also
represents that it maintains policies and procedures reasonably designed to ensure compliance with sanctions administered by
the United States, the European Union, or any individual European Union member state, including the United Kingdom, to the
extent applicable to it. The Investor further represents that the funds held by the Investor and used to purchase the Shares
were legally derived and were not obtained, directly or indirectly, from a Prohibited Investor.

(m)
If the Investor is or is acting on behalf of (i) an employee benefit plan that is subject to Title I of the Employee
Retirement Income Security Act of 1974, as amended (“ERISA”), (ii) a plan, an individual retirement
account or other arrangement that is subject to Section 4975 of the Internal Revenue Code of 1986, as amended (the
“Code”), (iii) an entity whose underlying assets are considered to include “plan assets” of
any such plan, account or arrangement described in clauses (i) and (ii) (each, an “ERISA Plan”), or (iv)
an employee benefit plan that is a governmental plan (as defined in Section 3(32) of ERISA), a church plan (as defined in
Section 3(33) of ERISA), a non-U.S. plan (as described in Section 4(b)(4) of ERISA) or other plan that is not subject to the
foregoing clauses (i), (ii) or (iii) but may be subject to provisions under any other federal, state, local, non-U.S. or
other laws or regulations that are similar to such provisions of ERISA or the Code (collectively, “Similar
Laws,” and together with ERISA Plans, “Plans”), the Investor represents and warrants that (A)
neither Ignyte nor any of its affiliates has provided investment advice or has otherwise acted as the Plan’s fiduciary,
with respect to its decision to acquire and hold the Shares, and none of the parties to the Transaction is or shall at any
time be the Plan’s fiduciary with respect to any decision in connection with the Investor’s investment in the
Shares; and (B) its purchase of the Shares will not result in a non-exempt prohibited transaction under Section 406 of ERISA
or Section 4975 of the Code, or any applicable Similar Law.

6

(n)
The Investor is not a foreign person (as defined in 31 C.F.R. Part 800.224) in which the national or subnational
governments of a single foreign state have a substantial interest (as defined in 31 C.F.R. Part 800.244).

(o)
The Investor has or has commitments to have and, when required to deliver payment to Ignyte pursuant to Section 2
above, will have, sufficient funds to pay the Subscription Amount and consummate the purchase and sale of the Shares pursuant
to this Purchase Agreement.

(p)
The Investor acknowledges that Ignyte continues to review the SEC Statement, Redeemable Share Classification Changes
and their respective implications, including on the financial statements and other information included in its SEC Reports,
and any restatement, revision or other modification of the SEC Reports relating to or arising from such review, any
subsequent related agreements or any other guidance from the Staff of the SEC with respect to the SEC Statement or Redeemable
Share Classification Changes shall be deemed not material for purposes of this Agreement.

(q)
No broker or finder is entitled to any brokerage or finder’s fee or commission payable by the Investor solely in
connection with the sale of the Shares to the Investor based on any arrangement entered into by or on behalf of the
Investor.

7.
No Hedging. The Investor hereby agrees that neither it, its controlled affiliates, nor any person or entity acting on its
or its controlled affiliates’ behalf or pursuant to any understanding with it, shall execute any short sales (as such term
is defined in Regulation SHO under the Exchange Act, 17 CFR 242.200) or engage in other hedging transactions of any kind with
respect to the Shares during the period from the date of this Purchase Agreement through the Closing date (or such earlier termination
of this Purchase Agreement). Nothing in this Section 7 shall prohibit (x) any other investment portfolios or departments or groups
of Investor that have no knowledge of this Purchase Agreement or of the Investor’s participation in this transaction and
have not been informed by the Investor of the Transaction (including Investor’s controlled affiliates and/or affiliates)
from entering into any short sales or engaging in other hedging transactions or (y) any portfolio company or third-party investment
manager engaged by Investor that may engage in any short sales or hedging transactions on Investor’s behalf, if such portfolio
company or third-party investment manager has not been directed or instructed to engage in short sales or hedging transactions
with respect to the Shares by the Investor or any of the persons that are subject to the foregoing.

8.
Registration Rights.

(a)
Ignyte agrees that, within thirty (30) calendar days following the Closing Date (such deadline, the “Filing
Deadline”), Ignyte will submit to or file with the SEC a registration statement for a shelf registration on Form
S-1 or Form S-3 (if Ignyte is then eligible to use a Form S-3 shelf registration) (the “Registration
Statement”), in each case, covering the resale of the Shares acquired by the Investor pursuant to this Purchase
Agreement which are eligible for registration (determined as of two (2) business days prior to such submission or filing)
(the “Registrable Shares”) and Ignyte shall use its commercially reasonable efforts to have the
Registration Statement declared effective as soon as practicable after the filing thereof, but no later than the earlier of
(i) the 90th calendar day following the filing date thereof if the SEC notifies Ignyte that it will “review” the
Registration Statement and (ii) the 10th business day after the date Ignyte is notified (orally or in writing, whichever is
earlier) by the SEC that the Registration Statement will not be “reviewed” or will not be subject to further
review (such earlier date, the “Effectiveness Deadline”); provided, however, that
Ignyte’s obligations to include the Registrable Shares in the Registration Statement are contingent upon the Investor
furnishing in writing to Ignyte such information regarding the Investor or its permitted assigns, the securities of Ignyte
held by the Investor and the intended method of disposition of the Registrable Shares (which shall be limited to
non-underwritten public offerings) as shall be reasonably requested by Ignyte to effect the registration of the Registrable
Shares, and the Investor shall execute such documents in connection with such registration as Ignyte may reasonably request
that are customary of a selling stockholder in similar situations, including providing that Ignyte shall be entitled to
postpone and suspend the effectiveness or use of the Registration Statement, if applicable, as permitted hereunder; provided
that the Investor shall not in connection with the foregoing be required to execute any lock-up or similar agreement or
otherwise be subject to any contractual restriction on the ability to transfer the Registrable Shares. For as long as the
Investor holds Shares, Ignyte will use commercially reasonable efforts to file all reports for so long as the condition in
Rule 144(c)(1) (or Rule 144(i)(2), if applicable) is required to be satisfied, and provide all customary and reasonable
cooperation, necessary to enable the undersigned to resell the Shares pursuant to Rule 144 under the Securities Act (in each
case, when Rule 144 under the Securities Act becomes available to the Investor). Any failure by Ignyte to file the
Registration Statement by the Filing Deadline or to effect such Registration Statement by the Effectiveness Deadline shall
not otherwise relieve Ignyte of its obligations to file or effect the Registration Statement as set forth above in this Section
8.

7

(b)
At its expense Ignyte shall:

(i) except for such times as Ignyte is permitted hereunder to suspend the use of the prospectus forming part of a Registration
Statement, use its commercially reasonable efforts to keep such registration, and any qualification, exemption or compliance under
state securities laws which Ignyte determines to obtain, continuously effective with respect to the Investor, and to keep the
applicable Registration Statement or any subsequent shelf registration statement free of any material misstatements or omissions,
until the earlier of the following: (A) the Investor ceases to hold any Registrable Shares, (B) the date all Registrable Shares
held by the Investor may be sold without restriction under Rule 144, including without limitation, any volume and manner of sale
restrictions which may be applicable to affiliates under Rule 144 under the Securities Act and without the requirement for Ignyte
to be in compliance with the current public information required under Rule 144(c)(1) (or Rule 144(i)(2), if applicable) under
the Securities Act, and (C) two (2) years from the date of effectiveness of the Registration Statement. The period of time during
which Ignyte is required hereunder to keep a Registration Statement effective is referred to herein as the “Registration
Period”;

(ii)
during the Registration Period, advise the Investor, as expeditiously as possible:

(1) when a Registration Statement or any amendment thereto has been filed with the SEC;

(2)
after it shall receive notice or obtain knowledge thereof, of the issuance by the SEC of any stop order suspending the
effectiveness of any Registration Statement or the initiation of any proceedings for such purpose;

(3) of the receipt by Ignyte of any notification with respect to the suspension of the qualification of the Registrable Shares included
therein for sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and

(4) subject to the provisions in this Purchase Agreement, of the occurrence of any event that requires the making of any changes
in any Registration Statement or prospectus so that, as of such date, the statements therein are not misleading and do not omit
to state a material fact required to be stated therein or necessary to make the statements therein (in the case of a prospectus,
in the light of the circumstances under which they were made) not misleading.

Notwithstanding
anything to the contrary set forth herein, Ignyte shall not, when so advising the Investor of such events, provide the Investor
with any material, nonpublic information regarding Ignyte other than to the extent that providing notice to the Investor of the
occurrence of the events listed in (1) through (4) above constitutes material, nonpublic information regarding Ignyte;

8

(iii) during the Registration Period, use its commercially reasonable efforts to obtain the withdrawal of any order suspending
the effectiveness of any Registration Statement as soon as reasonably practicable;

(iv)
during the Registration Period, upon the occurrence of any event contemplated in Section 8(b)(ii)(4) above, except for
such times as Ignyte is permitted hereunder to suspend, and has suspended, the use of a prospectus forming part of
a Registration Statement, Ignyte shall use its commercially reasonable efforts to as soon as reasonably practicable prepare
a post-effective amendment to such Registration Statement or a supplement to the related prospectus, or file any other
required document so that, as thereafter delivered to purchasers of the Registrable Shares included therein, such prospectus
will not include any untrue statement of a material fact or omit to state any material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading;

(v)
during the Registration Period, use its commercially reasonable efforts to cause all Registrable Shares to be listed on each
securities exchange or market, if any, on which the Shares have been listed;

(vi) during the Registration Period, use its commercially reasonable efforts to allow the Investor to review disclosure regarding the
Investor in the Registration Statement; and

(vii) during the Registration Period, otherwise, in good faith, cooperate reasonably with, and take such customary actions as may reasonably
be requested by the Investor, consistent with the terms of this Agreement, in connection with the registration of the Registrable
Shares.

(c) Notwithstanding anything to the contrary in this Purchase Agreement, Ignyte shall be entitled to delay the filing or effectiveness
of, or suspend the use of, the Registration Statement if it determines (i) that in order for the Registration Statement not to
contain a material misstatement or omission, (x) an amendment thereto would be needed to include information that would at that
time not otherwise be required in a current, quarterly, or annual report under the Exchange Act or (y) the negotiation or consummation
of a transaction by Ignyte or its subsidiaries is pending or an event has occurred, which negotiation, consummation or event Ignyte’s
board of directors reasonably believes would require additional disclosure by Ignyte in the Registration Statement of material
information that Ignyte has a bona fide business purpose for keeping confidential and the non-disclosure of which in the Registration
Statement would be expected, in the reasonable determination of Ignyte’s board of directors to cause the Registration Statement
to fail to comply with applicable disclosure requirements, or (ii) such delay or suspension arises out of, or is a result of,
or is related to or is in connection with the SEC Statement, Redeemable Share Classification Changes or other accounting matters,
or any related disclosure or other matters (each such circumstance, a “Suspension Event”); provided,
however, that Ignyte may not delay or suspend the Registration Statement on more than three occasions or for more than
ninety (90) consecutive calendar days, or more than one hundred and twenty (120) total calendar days in each case during any twelve-month
period. Upon receipt of any written notice from Ignyte of the happening of any Suspension Event during the period that the Registration
Statement is effective or if as a result of a Suspension Event the Registration Statement or related prospectus contains any untrue
statement of a material fact or omits to state any material fact required to be stated therein or necessary to make the statements
therein (in light of the circumstances under which they were made, in the case of the prospectus) not misleading, the Investor
agrees that (i) it will immediately discontinue offers and sales of the Registrable Shares under the Registration Statement (excluding,
for the avoidance of doubt, sales conducted pursuant to Rule 144) until the Investor receives copies of a supplemental or amended
prospectus (which Ignyte agrees to promptly prepare) that corrects the misstatement(s) or omission(s) referred to above and receives
notice that any post-effective amendment has become effective or unless otherwise notified by Ignyte that it may resume such offers
and sales, and (ii) it will maintain the confidentiality of any information included in such written notice delivered by Ignyte
unless otherwise required by law or subpoena. If so directed by Ignyte, the Investor will deliver to Ignyte or, in the Investor’s
sole discretion destroy, all copies of the prospectus covering the Registrable Shares in the Investor’s possession; provided,
however, that this obligation to deliver or destroy all copies of the prospectus covering the Registrable Shares shall not
apply (A) to the extent Investor is required to retain a copy of such prospectus (1) in order to comply with applicable legal,
regulatory, self-regulatory or professional requirements or (2) in accordance with a bona fide pre-existing document retention
policy or (B) to copies stored electronically on archival servers as a result of automatic data back-up.

(d) Indemnification.

9

(i) Ignyte agrees to indemnify, to the extent permitted by law, the Investor (to the extent a seller under the Registration Statement),
its directors, officers, partners, managers, members, stockholders, agents and each person who controls the Investor (within the
meaning of the Securities Act), to the extent permitted by law, against all losses, claims, damages, liabilities and reasonable
and documented out of pocket expenses (including reasonable and documented attorneys’ fees of one law firm) caused by any
untrue or alleged untrue statement of material fact contained in any Registration Statement, prospectus included in any Registration
Statement (“Prospectus”) or preliminary Prospectus or any amendment thereof or supplement thereto or any omission
or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case
of a Prospectus, in the light of the circumstances under which they were made) not misleading, except insofar as the same are
caused by or contained in any information or affidavit so furnished in writing to Ignyte by or on behalf of the Investor expressly
for use therein.

(ii)
In connection with any Registration Statement in which the Investor is participating, the Investor shall furnish (or cause
to be furnished) to Ignyte in writing such information and affidavits as Ignyte reasonably requests for use in connection
with any such Registration Statement or Prospectus and, to the extent permitted by law, shall indemnify Ignyte, its directors
and officers and each person or entity who controls Ignyte (within the meaning of the Securities Act) against any losses,
claims, damages, liabilities and expenses (including, without limitation, reasonable outside attorneys’ fees) resulting
from any untrue or alleged untrue statement of material fact contained or incorporated by reference in any Registration
Statement, Prospectus or preliminary Prospectus or any amendment thereof or supplement thereto or any omission or alleged
omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of a
Prospectus, in the light of the circumstances under which they were made) not misleading, but only to the extent that such
untrue statement or omission is contained (or not contained in, in the case of an omission) in any information or affidavit
so furnished in writing by or on behalf of the Investor expressly for use therein; provided, however, that the
liability of the Investor shall be several and not joint with any other investor and shall be limited to the net proceeds
received by the Investor from the sale of Registrable Shares giving rise to such indemnification obligation.

(iii) Any person or entity entitled to indemnification herein shall (A) give prompt written notice to the indemnifying party
of any claim with respect to which it seeks indemnification (provided that the failure to give prompt notice shall not
impair any person’s or entity’s right to indemnification hereunder to the extent such failure has not prejudiced
the indemnifying party) and (B) unless in such indemnified party’s reasonable judgment a conflict of interest between
such indemnified and indemnifying parties may exist with respect to such claim, permit such indemnifying party to assume the
defense of such claim with counsel reasonably satisfactory to the indemnified party. If such defense is assumed, the
indemnifying party shall not be subject to any liability for any settlement made by the indemnified party without its consent
(but such consent shall not be unreasonably withheld). An indemnifying party who is not entitled to, or elects not to, assume
the defense of a claim shall not be obligated to pay the fees and expenses of more than one counsel for all parties
indemnified by such indemnifying party with respect to such claim, unless in the reasonable judgment of legal counsel to any
indemnified party a conflict of interest exists between such indemnified party and any other of such indemnified parties with
respect to such claim. No indemnifying party shall, without the consent of the indemnified party, consent to the entry of any
judgment or enter into any settlement which cannot be settled in all respects by the payment of money (and such money is so
paid by the indemnifying party pursuant to the terms of such settlement) or which settlement includes a statement or
admission of fault and culpability on the part of such indemnified party or which does not include as an unconditional term
thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such
claim or litigation.

(iv) The indemnification provided for under this Purchase Agreement shall remain in full force and effect regardless of any investigation
made by or on behalf of the indemnified party or any officer, director or controlling person or entity of such indemnified party
and shall survive the transfer of securities.

10

(v) If the indemnification provided under this Section 8(d) from the indemnifying party is unavailable or insufficient to
hold harmless an indemnified party in respect of any losses, claims, damages, liabilities and expenses referred to herein,
then the indemnifying party, in lieu of indemnifying the indemnified party, shall contribute to the amount paid or payable by
the indemnified party as a result of such losses, claims, damages, liabilities and expenses in such proportion as is
appropriate to reflect the relative fault of the indemnifying party and the indemnified party, as well as any other relevant
equitable considerations; provided, however, that the liability of the Investor shall be limited to the net
proceeds received by the Investor from the sale of Registrable Shares giving rise to such indemnification obligation. The
relative fault of the indemnifying party and indemnified party shall be determined by reference to, among other
things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission
or alleged omission to state a material fact, was made by (or not made by, in the case of an omission), or relates
to information supplied by (or not supplied by, in the case of an omission), such indemnifying party or indemnified party,
and the indemnifying party’s and indemnified party’s relative intent, knowledge, access to information
and opportunity to correct or prevent such action. The amount paid or payable by a party as a result of the losses or
other liabilities referred to above shall be deemed to include, subject to the limitations set forth in Sections
8(d)(i), (ii) and (iii) above, any legal or other fees, charges or expenses reasonably incurred by such
party in connection with any investigation or proceeding. No person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) shall be entitled to contribution pursuant to this Section 8(d)(v)
from any person or entity who was not guilty of such fraudulent misrepresentation.

(vi) If
the Shares acquired hereunder are either eligible to be sold (i) pursuant to an effective Registration Statement or (ii) without
restriction under, and without Ignyte being in compliance with the current public information requirements of, Rule 144 under
the Securities Act, then at the Investor’s request, Ignyte will reasonably cooperate with Ignyte’s transfer agent,
such that any remaining restrictive legend set forth on such Shares will be removed in connection with a sale of such shares.

9. Termination.
This Purchase Agreement shall terminate and be void and of no further force and effect, and all rights and obligations of the
parties hereunder shall terminate without any further liability on the part of any party in respect thereof, upon the earliest
to occur of (a) such date and time as the Transaction Agreement is terminated in accordance with its terms, (b) upon the mutual
written agreement of each of the parties hereto to terminate this Purchase Agreement, (c) if the conditions to Closing set forth
in Section 3 of this Purchase Agreement are not satisfied at, or are not capable of being satisfied on or prior to, the
Closing and, as a result thereof, the transactions contemplated by this Purchase Agreement will not be or are not consummated
at the Closing and (d) the Outside Date (as defined in the Transaction Agreement) if the closing of the Transaction has not occurred
on or before such date; provided that nothing herein will relieve any party from liability for any willful breach hereof
prior to the time of termination, and each party will be entitled to any remedies at law or in equity to recover losses, liabilities
or damages arising from any such willful breach. Ignyte shall notify the Investor of the termination of the Transaction Agreement
promptly after the termination of such agreement. Upon the termination of this Purchase Agreement in accordance with this Section
9, any monies paid by the Investor to Ignyte in connection herewith shall be promptly (and in any event within two (2) business
days after such termination) returned to the Investor.

10. Trust
Account Waiver. The Investor acknowledges that Ignyte is a blank check company with the powers and privileges to effect
a merger, asset acquisition, reorganization or similar business combination involving Ignyte and one or more businesses or
assets. The Investor further acknowledges that, as described in Ignyte’s prospectus relating to its initial public
offering dated January 27, 2021 (the “IPO Prospectus”) available at www.sec.gov, substantially all of
Ignyte’s assets consist of the cash proceeds of Ignyte’s initial public offering and private placement of its
securities, and substantially all of those proceeds have been deposited in a trust account (the “Trust
Account”) for the benefit of Ignyte, its public stockholders and the underwriter of Ignyte’s initial public
offering. Except with respect to interest earned on the funds held in the Trust Account that may be released to Ignyte to pay
its tax obligations, if any, the cash in the Trust Account may be disbursed only for the purposes set forth in the IPO
Prospectus. For and in consideration of Ignyte entering into this Purchase Agreement, the receipt and sufficiency of which
are hereby acknowledged, the Investor hereby irrevocably waives any and all right, title and interest, or any claim of any
kind it has or may have in the future, in or to any monies held in the Trust Account, and agrees not to seek recourse against
the Trust Account as a result of, or arising out of, this Purchase Agreement; provided, that nothing in this Section
10 shall be deemed to limit the Investor’s right, title, interest or claim to the Trust Account by virtue of the
Investor’s record or beneficial ownership of Ignyte Common Stock acquired by any means other than pursuant to this
Purchase Agreement.

11

11. Miscellaneous.

(a) Purchase
Neither this Purchase Agreement nor any rights that may accrue to the Investor hereunder (other than the Shares acquired hereunder,
if any) may be transferred or assigned, other than an assignment
to any fund or account managed by the same investment manager as the Investor or an affiliate thereof, subject to, if such transfer
or assignment is prior to the Closing, such transferee or assignee, as applicable, executing a joinder to this Purchase Agreement
or a separate subscription agreement in substantially the same form as this Purchase Agreement, including with respect to the
Purchase Amount and other terms and conditions, provided, that, in the case of any such transfer or assignment, the initial
party to this Purchase Agreement shall remain bound by its obligations under this Purchase Agreement in the event that the transferee
or assignee, as applicable, does not comply with its obligations to consummate the purchase of Shares contemplated hereby. Neither
this Purchase Agreement nor any rights that may accrue to Ignyte hereunder or any of Ignyte’s obligations may be transferred
or assigned other than pursuant to the Transaction.

(b) Ignyte
may request from the Investor such additional information as Ignyte may deem necessary to evaluate the eligibility of the Investor
to acquire the Shares and in connection with the inclusion of the Shares in the Registration Statement, and the Investor shall
provide such information as may reasonably be requested, to the extent readily available and to the extent consistent with its
internal policies and procedures. The Investor acknowledges that Ignyte may file a form of this Purchase Agreement with the SEC
as an exhibit to a current or periodic report or a registration statement of Ignyte.

(c) The
Investor acknowledges that Ignyte will rely on the acknowledgments, understandings, agreements, representations and warranties
of the Investor contained in this Purchase Agreement. Prior to the Closing, the Investor agrees to promptly notify Ignyte if any
of the acknowledgments, understandings, agreements, representations and warranties of the Investor set forth herein are no longer
accurate.

(d) Ignyte
and the Investor are each entitled to rely upon this Purchase Agreement and each is irrevocably authorized to produce this Purchase
Agreement or a copy hereof to any interested party in any administrative or legal proceeding or official inquiry with respect
to the matters covered hereby.

(e) All
of the representations and warranties contained in this Purchase Agreement shall survive the Closing. All of the covenants and
agreements made by each party hereto in this Purchase Agreement shall survive the Closing until the applicable statute of limitations
or in accordance with their respective terms, if a shorter period.

(f) This
Purchase Agreement may not be modified, waived or terminated (other than pursuant to the terms of Section 9 above) except
by an instrument in writing, signed by each of the parties hereto and, to the extent required by the Transaction Agreement, the
Company. No failure or delay of either party in exercising any right or remedy hereunder shall operate as a waiver thereof, nor
shall any single or partial exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such
right or power, or any course of conduct, preclude any other or further exercise thereof or the exercise of any other right or
power. The rights and remedies of the parties and third-party beneficiaries hereunder are cumulative and are not exclusive of
any rights or remedies that they would otherwise have hereunder.

(g) This
Purchase Agreement (including the schedule hereto) constitutes the entire agreement, and supersedes all other
prior agreements, understandings, representations and warranties, both written and oral, among the parties, with respect to
the subject matter hereof. Except as set forth in Section 8(d), Section 11(c) and Section 11(d) with
respect to the persons referenced therein, this Purchase Agreement shall not confer any rights or remedies upon any person
other than the parties hereto, and their respective successor and assigns.

(h) Except
as otherwise provided herein, this Purchase Agreement shall be binding upon, and inure to the benefit of the parties hereto and
their heirs, executors, administrators, successors, legal representatives, and permitted assigns, and the agreements, representations,
warranties, covenants and acknowledgments contained herein shall be deemed to be made by, and be binding upon, such heirs, executors,
administrators, successors, legal representatives and permitted assigns.

(i) If
any provision of this Purchase Agreement shall be adjudicated by a court of competent jurisdiction to be invalid, illegal or unenforceable,
the validity, legality or enforceability of the remaining provisions of this Purchase Agreement shall not in any way be affected
or impaired thereby and shall continue in full force and effect.

12

(j) Each
party shall pay all of its own costs and expenses incurred in anticipation of, relating to and in connection with the negotiation
and execution of this Purchase Agreement and the transactions contemplated hereby, whether or not such transactions are consummated.

(k) This
Purchase Agreement may be executed in one or more counterparts (including by electronic mail or in .pdf) and by different parties
in separate counterparts, with the same effect as if all parties hereto had signed the same document. All counterparts so executed
and delivered shall be construed together and shall constitute one and the same agreement.

(l) The
parties hereto acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Purchase
Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that
the parties shall be entitled to an injunction or injunctions to prevent breaches of this Purchase Agreement, without posting
a bond or undertaking and without proof of damages, to enforce specifically the terms and provisions of this Purchase Agreement,
this being in addition to any other remedy to which such party is entitled at law, in equity, in contract, in tort or otherwise.

(m) THE
PARTIES HERETO IRREVOCABLY SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE COURT OF CHANCERY OF THE STATE OF DELAWARE (OR, TO
THE EXTENT SUCH COURT DOES NOT HAVE SUBJECT MATTER JURISDICTION, THE SUPERIOR COURT OF THE STATE OF DELAWARE, OR THE UNITED
STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE) SOLELY IN RESPECT OF THE INTERPRETATION AND ENFORCEMENT OF THE PROVISIONS
OF THIS PURCHASE AGREEMENT AND THE DOCUMENTS REFERRED TO IN THIS PURCHASE AGREEMENT AND IN RESPECT OF THE TRANSACTIONS
CONTEMPLATED HEREBY, AND HEREBY WAIVE, AND AGREE NOT TO ASSERT, AS A DEFENSE IN ANY ACTION, SUIT OR PROCEEDING FOR
INTERPRETATION OR ENFORCEMENT HEREOF OR ANY SUCH DOCUMENT THAT IS NOT SUBJECT THERETO OR THAT SUCH ACTION, SUIT OR PROCEEDING
MAY NOT BE BROUGHT OR IS NOT MAINTAINABLE IN SAID COURTS OR THAT VENUE THEREOF MAY NOT BE APPROPRIATE OR THAT THIS PURCHASE
AGREEMENT OR ANY SUCH DOCUMENT MAY NOT BE ENFORCED IN OR BY SUCH COURTS, AND THE PARTIES HERETO IRREVOCABLY AGREE THAT ALL
CLAIMS WITH RESPECT TO SUCH ACTION, SUIT OR PROCEEDING SHALL BE HEARD AND DETERMINED BY SUCH A DELAWARE STATE OR FEDERAL
COURT. THE PARTIES HEREBY CONSENT TO AND GRANT ANY SUCH COURT JURISDICTION OVER THE PERSON OF SUCH PARTIES AND OVER THE
SUBJECT MATTER OF SUCH DISPUTE AND AGREE THAT MAILING OF PROCESS OR OTHER PAPERS IN CONNECTION WITH SUCH ACTION, SUIT OR
PROCEEDING IN THE MANNER PROVIDED IN THIS SECTION 11(m) OF THIS PURCHASE AGREEMENT OR IN SUCH OTHER MANNER AS MAY BE
PERMITTED BY LAW SHALL BE VALID AND SUFFICIENT SERVICE THEREOF. THIS PURCHASE AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED
IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE, WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS THAT WOULD
OTHERWISE REQUIRE THE APPLICATION OF THE LAW OF ANY OTHER STATE.

(n) EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS PURCHASE AGREEMENT OR THE TRANSACTIONS CONTEMPLATED
HEREBY IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY IRREVOCABLY AND UNCONDITIONALLY
WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR
RELATING TO THIS PURCHASE AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS PURCHASE AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES
THAT (I) NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY
WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER; (II) SUCH PARTY UNDERSTANDS AND HAS CONSIDERED THE
IMPLICATIONS OF THE FOREGOING WAIVER; (III) SUCH PARTY MAKES THE FOREGOING WAIVER VOLUNTARILY; AND (IV) SUCH PARTY HAS BEEN INDUCED
TO ENTER INTO THIS PURCHASE AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVER AND CERTIFICATIONS IN THIS SECTION 11(n).

13

12. Non-Reliance
and Exculpation. The Investor acknowledges that it is not relying upon, and has not relied upon, any statement,
representation or warranty made by any person, firm or corporation (including, without limitation, Ignyte and any of its
affiliates, any control persons, officers, directors, employees, partners, agents, representatives, legal counsel, financial
advisors or accountants), other than the statements, representations and warranties of Ignyte expressly contained in Section
5 of this Purchase Agreement, in making its investment or decision to invest in Ignyte. The Investor acknowledges and
agrees that none of (i) the Other Investors pursuant to this Purchase Agreement or any Other Subscription Agreement related
to the private placement of the Shares (including the Other Investors’ respective affiliates or any control persons,
officers, directors, employees, partners, agents or representatives of any of the foregoing), (ii) any other party to the
Transaction Agreement (other than Ignyte), or (iii) any affiliates, or any control persons, officers, directors, employees,
partners, agents or representatives of any of Ignyte, the Company or any other party to the Transaction Agreement shall be
liable to the Investor, or to any Other Investor, pursuant to this Purchase Agreement or any Other Subscription Agreement
related to the private placement of the Shares, the negotiation hereof or thereof or the subject matter hereof or thereof, or
the transactions contemplated hereby or thereby, for any action heretofore or hereafter taken or omitted to be taken by any
of them in connection with the purchase of the Shares.

13. Press
Releases. Ignyte shall, by 9:00 a.m., New York City time, on the first business day immediately following the date of
this Purchase Agreement, issue one or more press releases or furnish or file with the SEC a Current Report on Form 8-K
(collectively, the “Disclosure Document”) disclosing, to the extent not previously publicly disclosed, the
PIPE investments related hereto, all material terms of the Transaction and any other material, non-public information that
Ignyte, or any of its officers, employees or agents on behalf of Ignyte, has provided to the Investor at any time prior to
the filing of the Disclosure Document. From and after the disclosure of the Disclosure Document, the Investor shall no longer
be subject to any confidentiality or similar obligations under any current agreement, whether written or oral, with Ignyte or
any of its affiliates, and, to the knowledge of Ignyte, the Investor shall not be in possession of any material, non-public
information received from Ignyte or any of its officers, directors, employees or agents. All press releases or other public
communications relating to the transactions contemplated hereby between Ignyte and the Investor, and the method of the
release for publication thereof, shall be subject to the prior approval of (i) Ignyte, and (ii) the Investor to the extent
such press release or public communication references the Investor or its affiliates or investment advisers by name or any
trademark owned by the Investor, its affiliates or its investment advisers. The restriction in this Section 13 shall
not apply to the extent the public announcement is required by applicable securities law, any governmental authority or stock
exchange rule; provided, that in such an event, the applicable party shall use its commercially reasonable efforts to
consult with the other party in advance as to its form, content and timing.

14. Notices. All notices and other communications among the parties shall be in writing and shall be deemed to have been duly
given (i) when delivered in person, (ii) when delivered after posting in the United States mail having been sent registered or
certified mail return receipt requested, postage prepaid, (iii) when delivered by FedEx or other nationally recognized overnight
delivery service, or (iv) when delivered by email (in each case in this clause (iv), solely if receipt is confirmed, but excluding
any automated reply, such as an out-of-office notification), addressed as follows:

If
to the Investor, to the address provided on the Investor’s signature page hereto.

If
to Ignyte, to:

	Ignyte
    Acquisition Corp.	 
	640
    Fifth Avenue	 
	New
    York, New York 10019	 
	Attention:	David Rosenberg,
    Co-Chief Executive Officer
	 	David J. Strupp,
    Jr., Co-Chief Executive Officer
	Email:	drosenberg@ignytespac.com
	 	dstrupp@ignytespac.com
	 
	
	 

14

	with copies to (which shall not constitute notice), to:
	 	 
	DLA
    Piper LLP (US)	 
	51
    John F. Kennedy Parkway	 
	Suite
    120	 
	Short
    Hills, NJ 07078	 
	Attention:	Andrew P. Gilbert
	 	Scott A. Cowan
	Email:	andrew.gilbert@us.dlapiper.com
	 	scott.cowan@us.dlapiper.com
	If
    to the Company, to:	 
	 
	and	 
	 
	Peak
    Bio Co., Ltd.	 
	Building
    B #1009	 
	670
    Daewangpangyo-ro (Sampyeong-dong, U Space 2),
	Bundang-gu,
    Seongnam-si, Gyenggi-do 13494
	Attention:	Hoyoung Huh, Chief
    Executive Officer
	Email:	hoyoung.huh@ph-pharma.com
	 
	with
    copies to (which shall not constitute notice), to:
	 
	Bae,
    Kim & Lee LLC	 
	13F,
    Tower B, Centropolis,	 
	26
    Ujeongguk-ro, Jongno-gu, Seoul 03161
	Attention:
    Jung Min Jo	 
	Email:
    jungmin.jo@bkl.co.kr	 
	 
	and	 
	 
	BC
    Burr McCabe Law	 
	584
    Castro Street #882	 
	San
    Francisco, CA 94114	 
	Attention:
    Peter McCabe	 
	Email: pmccabe@bcbmlaw.com	 

or to
such other address or addresses as the parties may from time to time designate in writing. Copies delivered solely to outside
counsel shall not constitute notice.

SIGNATURE
PAGES FOLLOW

15

IN
WITNESS WHEREOF, the Investor has executed or caused this Purchase Agreement to be executed by its duly authorized representative
as of the date first set forth above.

	 	State/Country
    of Formation or Domicile:
	Name
    of Investor: Hoyoung Huh	 
	By:	 
	Name:	 
	Title:	 
	Name
    in which Shares are to be registered (if different):	 
	Investor’s
    EIN:	 
	Business
    Address-Street:	Mailing
    Address-Street (if different):
	City,
    State, Zip:	City,
    State, Zip:
	Attn:	Attn:
	Telephone
    No.:	Telephone
    No.:
	Facsimile
    No.:	Facsimile
    No.:
	Number
    of Shares subscribed for:	 
	Aggregate
    Subscription Amount:	Price
    Per Share: $10.00

You
must pay the Subscription Amount by wire transfer of United States dollars in immediately available funds to the account specified
by Ignyte in the Closing Notice.

Signature Page to Purchase
Agreement

IN
WITNESS WHEREOF, Ignyte has accepted this Purchase Agreement as of the date first set forth above.

	 	IGNYTE
    ACQUISITION CORP.
	 	 
	 	By	                
	 	NAME:
	 	TITLE:

Signature Page to Purchase
Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]